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 B. pseudomallei is a causative agent of melioidosis, a disease endemic in South 
East Asia, Northern Australia. The clinical presentations of melioidosis vary from 
asymptomatic to acute septic shock to chronic suppurative disease. Risk factors for this 
disease are Type 2 diabetes mellitus, chronic renal failure, alcoholism and thalassemia. 
To understand the host factors that predispose individuals to developing severe 
melioidosis, mouse models were used. We used in vivo mouse infection as well as in 
vitro mouse splenocyte infection to characterize the possible host factors that could 
contribute to the pathogenesis of melioidosis. With these models, we first examined the 
role of IL-10, an anti-inflammatory cytokine in melioidosis. We found that splenocytes 
from the susceptible BALB/c mice produced more IL-10 as compared to splenocytes 
from the relatively more resistant C57BL/6 mice. Neutralization of IL-10 in BALB/c 
bone marrow-derived macrophages showed an improved clearance of intracellular 
bacterial loads. Another mouse model we developed was used to examine the effect of 
glutathione in melioidosis. BALB/c mice deficient in glutathione were observed to die 
faster, had higher intracellular bacterial loads, and reduced production of the cytokines 
IL-12 and IFN-γ. We also discovered BipB, a T3SS3 effector protein from B. 
pseudomallei that could suppress cytokine production as well as host microbicidal 
activity. We believe that through our models, we can shed some light on the pathogenesis 
of B. pseudomallei.  
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1.1 MELIODOSIS, THE DISEASE 
1.1.1 MELIOIDOSIS 
 
 Melioidosis is a disease caused by the Gram-negative, saprophytic bacteria 
Burkholderia pseudomallei. In 1911, Whitmore and Krishnasawami described it as a 
“glanders-like” disease in morphine addicts in Rangoon, Burma (Whitmore and 
Krishnasawami 1912). The name “melioidosis” is derived from the Greek term "melis" 
(distemper of asses) and "eidos" (resemblance) by Stanton and Fletcher (Stanton and 
Fletcher 1921).  
 Burkholderia pseudomallei is found in soil and surface water in endemic regions. 
The bacterium can be selectively cultured using Ashdown’s agar (Ashdown 1979) where 
it exhibits “wrinkled” colony morphology. 
 
1.1.2 EPIDEMIOLOGY AND RISK FACTORS 
Melioidosis is mainly endemic in South-East Asia, the Indian subcontinent and 
Northern Australia (Currie et al 2008). The annual incidence rate in the Northern 
Territory of Australia from 1989 to 1999 for melioidosis was 16.5 per 100,000 people, 
with a peak of 41.7 per 100,000 due to high rainfall (Currie et al 2004). The Ubon 
Ratchathani province in northeast Thailand has annual incidence rates of about 4.4 per 
100,000 people (Suputtamongkol et al 1994), and other centres in northeast Thailand like 
Khon Kaen and Udon Thani also have large numbers of patients. In fact, melioidosis is 
the third leading cause of death in northeast Thailand, after HIV infection and 
tuberculosis (Limmathurotsakul et al 2010). Sporadic cases of melioidosis have also been 
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reported in Latin America, East and West Africa as well as the island of Madagascar 
(Currie et al 2008). 
 In Singapore itself, a total of 693 cases were observed from the period 1998-2007 
(Lo et al 2009). The year 2004 showed an increase in melioidosis cases, due to increased 
rainfall and flooding in Singapore. Out of these 693 cases, there were 112 deaths, giving 
an overall mortality rate of 16.2%. Mortality was associated with pre-existing diseases 
like diabetes, renal impairment, heart disease and hypertension (Lo et al 2009). Patients 
who developed bacteremic melioidosis also exhibited a higher fatality rate.  
The risk factors associated with melioidosis are mainly Type 2 diabetes mellitus 
and chronic renal disease (reviewed in Cheng and Currie 2005). Male gender and old age 
are also risk factors (Lo et al 2009) as is alcohol consumption (Currie et al 2010). 
However, HIV infection does not seem to be a risk factor (Chierakul et al 2004) in 
Thailand but this could be due to the difference in geographical distribution of the two 
diseases where melioidosis mainly affects rural people whereas HIV infects urban 
dwellers. 
1.1.3 PATIENTS WITH TYPE II DIABETES 
Diabetes mellitus is an important risk factor for developing acute melioidosis. 
Many other infections are also associated with diabetes, such as urinary tract infections, 
tuberculosis, pneumonias, foot infections (Joshi et al 1999, Muller et al 2004). There are 
several immunological defects associated with diabetes that predisposes humans to severe 
disease with many different infectious agents. 
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In diabetics, there are defects in neutrophil function, namely in terms of adherence, 
chemotaxis and phagocytosis (Delamaire et al 1997). Besides these defects, it was also 
found that there are defects in the oxidative burst produced by neutrophils to kill bacteria 
(Daoud et al 2009). Another mechanism by which neutrophils kill extracellular pathogens 
is by expulsion of chromatin which combines with granule proteins to form neutrophil 
extracellular traps (NETs). The formation of NETs was found to be inhibited by β-
hydroxybutyrate which is produced during diabetic ketoacidosis (Grinberg et al 2008). 
Taken together, neutrophil function in diabetics is compromised which could explain the 
susceptibility of diabetics to pathogens. 
The complement pathway is affected by hyperglycemia in diabetics as well 
because glucose attacks the thioester bond on complement C3, inhibiting it from binding 
to bacterial surface (Hostetter 1990).  
Monocytes, another component of the innate immune system also exhibit similar 
defects as neutrophils, i.e: chemotaxis and phagocytosis (Hill et al 1983, Geisler et al 
1982).  
Previously, many groups have documented the defects in the immune systems of 
Type II diabetics that may be the cause of increased susceptibility to B. pseudomallei 
infection.  Chanchamroen et al (2009) found impaired phagocytosis, reduced IL-8 
mediated migration and delayed apoptosis in neutrophils from diabetics compared to 
healthy subjects. Riyapa et al (2012) also found decreased levels of NETs secreted by 
neutrophils from diabetics. It was documented that there is an increased risk of 
developing meloidosis in diabetics with TLR-6-10 variants, compared to healthy controls 
(West et al 2012), perhaps due to altered TLR signalling. Diabetes is associated with 
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differences in coagulation, anti-coagulation and fibrinolysis compared to healthy subjects 
(Koh et al 2011). However, even though melioidosis also causes changes in the 
coagulation, anti-coagulation and fibrinolysis pathways, it was found that diabetes does 
not enhance these changes in these various pathways (Koh et al 2011).  
 
1.1.4 CLINICAL FEATURES  
Melioidosis is known as the “great mimicker” as its symptoms can resemble that of 
other diseases. The manifestations of this disease range from asymptomatic, acute septic 
shock, chronic localized disease or dormant infection (Leelarasamee 2004). Pneumonia is 
the most common presentation of this disease, seen in about half of the cases (Currie et al 
2010). Other symptoms of this disease include genito-urinary infection, arthritis, 
septicemia, cellulitis, and skin infection, showing the versatility of the bacterium in 
infecting many different organs in the human body. Abscesses in the liver, kidney, 
prostrate and skin can be seen in some patients as well in this disease (Currie et al 2010). 
Septic shock when seen in melioidosis patients is also associated with a higher mortality 
rate of 50% compared to non-septicemic melioidosis (Cheng et al 2010). Even when 
cured of the acute form of the disease, the bacterium may lay dormant inside the human 
body for decades before a relapse occurs. It has even been documented that one man 
developed melioidosis 62 years after his initial exposure to the bacterium, showing how 
well the bacterium can survive inside the human body (Ngauy et al 2005).  
Melioidosis is believed to be transmitted through three major routes, namely: 
inhalation, ingestion and inoculation through cuts and wounds on the skin. Inhalation was 
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postulated to be a route of infection due to reports of helicopter pilots during the Vietnam 
War who were exposed to soil containing B. pseudomallei during helicopter landings 
(Howe et al 1971). Also, outbreaks of the pneumonic form of melioidosis in Singapore 
correlated with periods of heavy rainfall, which could result in the aerosolization of the 
bacteria from the soil (Lo et al 2009). This was postulated to be the major mode of entry 
of the bacteria in Singapore as the majority of the patients did not have any exposure to 
wet soil contaminated with the bacterium (Lo et al 2009).  Besides inhalation, B. 
pseudomallei could also enter the human body through inoculation and ingestion. 
Inoculation was postulated to be a route of entry through studies in Australia (Currie et al 
2010) where the majority of patients had recreational or occupational exposure to soil, as 
well as in northeastern Thailand (Chaowagul et al 1989) where the people who are 
infected are mainly rice farmers.  
 
1.1.5 DIAGNOSIS 
Diagnosis of melioidosis by clinical features is difficult due to the various 
manifestations of the disease, as mentioned in the preceding paragraphs. The most 
definitive way of diagnosing melioidosis is by culture on agar from clinical specimens. A 
selective medium known as Ashdown’s agar (containing gentamicin) can be used to 
positively identify B. pseudomallei in the specimen via the formation of wrinkled 
colonies on the agar (Ashdown 1979). However, culture methods generally take a few 
days to show the presence of the bacteria, and time may be lost in administering the 
appropriate treatment.  
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Besides culture based methods, other methods are also being used for the diagnosis of 
melioidosis. One method that is used in Singapore is the indirect hemaglutination assay 
(Lo et al 2009) which detects antibodies against B. pseudomallei in patients. However 
this test has its drawbacks, as it may exhibit false positives in areas with high endemicity 
like Thailand (reviewed by Cheng and Currie et al 2005), but it may be quite useful for 
regions with low endemicity like Singapore. Antigen-based methods like direct 
immunofluorescence microscopy (Wuthiekanun et al 2005) and latex agglutination 
systems (Wuthiekanun et al 2002) have high specificity and sensitivity in the diagnosis of 
melioidosis, but are not yet available commercially for hospitals. These tests offer 
another advantage of being able to differentiate between B. pseudomallei and its avirulent 
relative, B. thailandensis. Recently, a new molecular diagnostic test was also developed. 
Termed “BurkDiff”, this real-time PCR assay uses a unique conserved region in B. 
pseudomallei and B. mallei (causative agent of glanders) to identify the bacteria, and 
differentiate between the two related pathogens (Bowers et al 2010).  This assay can 
enable rapid detection of the bacteria compared to traditional culture methods, and yet is 
sensitive to differentiate between closely related Burkholderia species. However, real-
time PCR requires expensive equipment and trained personnel, and this useful assay is 
not yet available commercially.  
 
1.1.6 TREATMENT 
B. pseudomallei is intrinsically resistant to many antibiotics like macrolides, 
aminoglycosides, most penicillins, and some cephalosporins (Livermore et al 1987, 
Moore et al 1999). This is due to the presence of beta-lactamases which acts on beta-
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lactam antibiotics like penicillins and cephalosporins, and the presence of efflux pumps 
which pump out antibiotics like aminoglycosides and macrolides. Thus, treatment of this 
disease is problematic.  
The treatment of melioidosis is divided into two phases: acute and eradication. For 
the acute phase, a high dose intravenous ceftazidime (a third generation cephalosporin) 
regime is the treatment of choice for melioidosis (White et al 1999). Ceftazidime can be 
combined with trimethoprim-sulfamethoxazole in the treatment. Other drugs used to treat 
melioidosis are the carbapenems (imipenem or meropenem). However, treatment failures 
do occur with ceftazidime due to the loss of penicillin binding protein-3 by the bacteria 
(Chantratita et al 2011). Hence, it is recommended to use a combinational drug therapy if 
the bacteria acquire ceftazidime resistance during the course of treatment.  The acute 
phase of treatment is then followed by the eradication phase of treatment for 6 months 
with the use of co-trimoxazole alone in Australia, whereas in Thailand, co-trimoxazole 
and doxycycline are used together (Cheng et al 2009). 
1.2 BACTERIA PATHOGENESIS AND VIRULENCE MECHANISMS 
1.2.4 BACTERIAL GENOMICS 
The genome of Burkholderia pseudomallei consists of two chromosomes, a large 
one which is 4.07 Mb long, and a smaller chromosome which is 3.17 Mb long (Holden et 
al 2004). The large chromosome encodes the core genome of the bacteria which includes 
genes essential for metabolism and cell growth,  that are mostly constitutively expressed. 
The small chromosome encodes many other genes that enable the bacteria to survive in 
various environmental niches as well as in various hosts like plants, animals and humans, 
and are regulated (Holden et al 2004). Within the bacterial genome, certain genes are 
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found to be positively selected (Nandi et al 2010). These genes are responsible for 
metabolism, membrane functions, cell signalling, and regulation of gene expression. 
However, amongst these positively selected genes, some are implicated in virulence in 
mammals like Type IV pili which the bacteria use for adhesion to host cells and 
movement, while some are responsible for the metabolism of taurine, an amino acid 
found exclusively only in mammals, demonstrating the ability of this bacteria in infecting 
animals.  
 
1.2.5 TYPE III SECRETION SYSTEMS 
The Type III secretion system (T3SS) is a major virulence mechanism used by 
many Gram-negative bacteria to inject effector proteins into the host cell, in both plants 
and animals, to modify its functions (reviewed by Hueck et al 1998). B. pseudomallei 
possesses three Type III secretion systems, of which T3SS3 (also known as bsa, 
Burkholderia secretion apparatus) is important for virulence in animals as seen in murine 
models of infection (Stevens et al 2004) as well as hamster models of infection (Warawa 
and Woods 2005). This T3SS3 is similar to the T3SS of Salmonella and Shigella, both 
well-known animal pathogens (Stevens et al 2002). T3SS3 has been implicated in 
caspase-1 mediated cell death in macrophages (Sun et al 2005), escape of bacteria from 
endocytic vesicles in phagocytes (Muangsombut et al 2008), interference with host 
eukaryotic cell cycle (Boh et al 2011), and escape from autophagy (Gong et al 2011). 
The other Type III secretion systems, T3SS1 and T3SS2, are more similar to those of 
Ralstonia, a plant pathogen (Attree and Attree 2011), and have only been shown to be 




1.2.6 TYPE VI SECRETION SYSTEM 
Besides the Type III secretion systems, B. pseudomallei also possesses six Type 
VI secretion systems (T6SS). One of them, T6SS1 is found to be a major virulence 
determinant in mouse and Syrian hamster models of infection (Burtnick et al 2011, Chen 
et al 2011, Pilaz et al 2006) as mice vaccinated with T6SS1 proteins were partially 
protected against B. pseudomallei challenge, and Syrian hamsters showed increased 
survival when infected with T6SS1 mutants when compared to wildtype B. pseudomallei. 
T6SS1 is also implicated in multi-nucleated giant cell (MNGC) formation, intracellular 
replication of the bacteria, and cytotoxicity in RAW 264.7 macrophages (Burtnick et al 
2011, Chen et al 2011). In fact, the regulation of T6SS1 is controlled by T3SS3 (Chen et 
al 2011), which in turn is under the control of bspR, a TetR family regulator (Sun et al 
2010), showing that the regulation of these virulence factors are intertwined.  
 
1.2.7 CELL SURFACE AND SECRETED VIRULENCE FACTORS 
Besides Type III and Type VI secretion systems, B. pseudomallei possesses other 
virulence factors as well. One of these virulence factors is the capsular polysaccharide. 
This capsular polysaccharide inhibits complement deposition on the surface of the 
bacteria (Reckseidler-Zenteno et al 2005), and mediates resistance against anti-microbial 
peptides like lactoferrin and histatins (Wikraiphat et al 2009). The lipopolysaccharide 
(LPS) of B. pseudomallei also confers resistance to killing by serum (DeShazer et al 
1998). Flagella, which are required by bacteria for motility is another virulence factor, as 
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it has been shown to be required for invasion into phagocytic and non-phagocytic cells 
(Chuaygud et al 2008), and  B. pseudomallei flagella mutants were avirulent when mice 
were infected with them (Chua et al 2003). Lastly, B. pseudomallei possesses Type IV 
pili, PilA, which is needed to mediate adhesion to epithelial cells, and mutants deficient 
in PilA were less virulent in nematode and murine models of infection (Essex-Lopresti et 
al 2005). 
Besides these cell surface virulence factors, B. pseudomallei also secretes 
enzymes that are anti-macrophage in nature, as a genome-wide screen for gain of 
function of B. pseudomallei identified these secreted factors (Dowling et al 2010). These 
anti-macrophage factors include putative hemolysins, elastases, phospholipases, 
metalloproteases, and other hypothetical toxin-like genes that are similar to Salmonella 
enterica SpvB that cause MNGC formation and induce apoptosis in macrophages when 
treated with lysates from E. coli expressing these toxin-like genes (Dowling et al 2010). 
Recently, it was discovered that B. pseudomallei secretes a cytotoxin that inhibits 
translation, which is structurally similar to Escherichia coli cytotoxic necrotizing factor 1 
(Cruz-Migoni et al 2011).  
To evade killing by phagocytes, B. pseudomallei produces superoxide dismutase 
C to break down reactive oxygen species produced by macrophages and neutrophils 
during the respiratory burst (Vanaporn et al 2011). 
Lastly, B. pseudomallei possesses a macrophage infectivity potentiator (Mip) 
which has peptidylprolyl cis-trans isomerase (PPIase) activity (Norville et al 2011). This 
Mip, BPSS1823, was found to be important for intracellular survival, protease production, 




1.3 MODELS FOR STUDYING MELIOIDOSIS 
B. pseudomallei has been found to infect many different species of animals such as 
camels, horses, sheep, goats, pigs, koalas, deers, cats, and dogs, However cattle, 
crocodiles and birds are relatively resistant to B. pseudomallei infection (reviewed in 
Cheng and Currie 2005). The use of small animals like rodents and nematodes has 
provided useful insights into the pathogenesis of the disease and have aided in the 
identification of virulence factors produced by the bacterium. 
 
1.3.4 MICE 
The most well-known model used for studying melioidosis is the mouse model, 
which utilizes the relatively susceptible BALB/c mice as compared to the more resistant 
C57BL/6 mice (Hoppe et al 1999). It was found that BALB/c mice were 10-100 fold 
more susceptible to B. pseudomallei infection as compared to C57BL/6 mice, depending 
on the route of infections (Liu et al 2002, Tan et al 2008). The intranasal and aerosol 
routes of infection had a lower LD50 compared to intraperitoneal and subcutaneous routes 
of infection (Tan et al 2008), but all showed that BALB/c mice were more susceptible to 
B. pseudomallei infection than C57BL/6. 
 In the past, the mouse models of BALB/c and C57BL/6 have focused on the acute 
aspect of melioidosis. Recently, it was found that by inoculating the relatively resistant 
C57BL/6 mice with a low dose (~100 cfu) of B. pseudomallei intranasally, a chronic 
form of melioidosis was produced in the mice which is similar to that observed in chronic 
melioidosis in humans (Conejero et al 2011). In this chronic melioidosis model, the mice 
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produced pro-inflammatory cytokines like TNF-α, IFN-γ, IL-6, and had granulomas and 
MNGCs, resembling that of latent tuberculosis infection and human chronic melioidosis 
(Conejero et al 2011). 
Recently, a Type 2 diabetic mouse model was also developed, which shows that 
altered macrophage function and hyper-production of pro-inflammatory cytokines were 
responsible for mortality in mice (Hodgson et al 2011). These mice carry a mutation in 
the leptin receptor which causes homozygotes (db/db) to become obsese and insulin 
resistant, resulting in Type II diabetes. This mouse model is better than the streptozocin 
induced diabetic mouse model (Chin et al 2012) as that model resembles Type I diabetes 
rather than Type II diabetes, due to the use of streptozocin to destroy pancreatic beta cells.  
 
1.3.5 CAENORHABDITIS ELEGANS 
Besides the widely used mice models, Caenorhabditis elegans, a nematode worm 
has also been studied in terms of its response to B. pseudomallei infection. Previous 
studies that were conducted using the C. elegans system have identified a diffusible-toxin 
as a possible virulence factor (O’Quinn et al 2001, Gan et al 2002). However, prolonged 
secretion of the unidentified toxin is required for killing of C. elegans (Lee et al 2011). 








1.3.6 OTHER RODENTS  
Besides mice, other rodents like rats and hamsters are also used as models for B. 
pseudomallei infection. Syrian hamsters have a LD50 of <10 cfu, using the 1026b strain 
and by the intra-peritoneal route (Jones et al 1997). This LD50 is considerably much 
lower when compared with infection of BALB/c mice. Also, the relative contributions of 
virulence factors to the pathogenesis of the disease are different between mice and 
hamsters. Flagella, a major virulence determinant in BALB/c mice infection, were found 
not to contribute much to the pathogenesis of the disease in Syrian hamsters (DeShazer et 
al 1997, Chua et al 2003). 
Sprague-Dawley rats have been used as animal models for both acute and chronic 
melioidosis, depending on the inoculum dose by the intra-tracheal route (van Shaik et al 
2008).  In that model, the histological sections of rat lungs from acute and chronic 
infection exhibited similar pathology to tuberculosis infection. Also, the rat infection 
model is able to quantify differences in virulence between B. pseudomallei strains during 
infection, making it helpful as a screen to identify virulence factors that may be different 
between the various B. pseudomallei strains. 
 
1.4 DIFFERENTIAL SUSCEPTIBILITY IN BALB/C AND C57BL/6 MICE 
In the preceding section, it was mentioned that the BALB/c mice were more 
susceptible to B. pseudomallei infection as compared to the C57BL/6 mice. To 
understand the basis of susceptibility to B. pseudomallei infection, Leakey et al (1998) 
performed limited genetic crosses, and showed that there is a genetic basis to resistance 
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to B. pseudomallei infection, and that genetic basis seems to lie on a single locus in the 
relatively more resistant C57BL/6 mice. 
The increased susceptibility of BALB/c mice was found not to be due to a lack of 
pro-inflammatory cytokines (e.g. TNF-α, IFN-γ or IL-1β) as BALB/c mice produced 
higher levels of these cytokines during B. pseudomallei infection as compared to 
C57BL/6 mice, at both transcript and protein levels (Liu et al 2002, Tan et al 2008, Ulett 
et al 2000). The excessive production of pro-inflammatory cytokines by BALB/c mice 
was due to the failure of the mice to control infection at an early stage (Liu et al 2002), 
leading to higher bacterial burden. Whereas in the C57BL/6 mice, moderate 
inflammatory responses were observed, and the mice were able to restrict bacterial 
burden after one day of infection (Hoppe et al 1999). As a result of the hyper-production 
of pro-inflammatory cytokines in BALB/c mice, immune-mediated pathology may result, 
leading to septic shock. In fact, the levels of these cytokines correlate with the severity of 
the disease (Lauw et al, Friedland et al 1998), showing that death is probably due to the 
result of septic shock induced by these cytokines.  
The differences in ability to restrict bacterial loads may be due to the different 
bactericidal mechanisms employed by the two strains of mice to contain B. pseudomallei 
infection as nitric oxide production was found to be detrimental in the C57BL/6 mice 
during B. pseudomallei infection but beneficial in BALB/c mice (Breitbach et al 2011), 
showing that C57BL/6 mice probably use a IFN-γ-dependent but nitric oxide-
independent pathway to control infection that is more efficient than BALB/c mice. One 
of these IFN-γ-dependent pathways is probably the NADPH oxidase pathway which 
utilizes reactive oxygen species (ROS) to kill bacteria in phagosomes (Brietbach et al 
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2006). However, even without the presence of IFN-γ stimulation, bone marrow-derived 
macrophages (BMMs) from BALB/c mice were less able to restrict bacterial growth 
compared to C57BL/6 BMMs at low multiplicities of infection, showing that C57BL/6 
macrophages probably have some innate bactericidal mechanisms that can restrict 
bacterial growth before the induction of IFN-γ (Brietbach et al 2006). 
During intravenous infection, it was also found that macrophages were the 
predominant cells that infiltrate lesions in C57BL/6 mice whereas in BALB/c mice, 
neutrophils were the predominant leukocyte cell type that infiltrate lesions. It was found 
that both macrophages and neutrophils play an important role in controlling B. 
pseudomallei infection (Brietbach et al 2006, Easton et al 2007) as depletion of these cell 
types resulted in increased mortality. However, a recent paper showed that the 
recruitment of neutrophils to sites of infection by B. pseudomallei by the action of IL-1β 
was detrimental in melioidosis as neutrophils were resistant to pyroptosis and failed to 
contain the bacteria, resulting in increased dissemination and excessive inflammation 
(Ceballos-Olvera et al 2011). Probably the systemic depletion of neutrophils (Easton et al 
2007) renders the host more susceptible by virtue of its immune-regulatory functions 
(Cassatella et al 2009) instead of its microbicidal functions. 
Taken together, these studies have shown that C57BL/6 mice are more resistant to 
B. pseudomallei infection as compared to BALB/c mice by virtue of the former being 
better at controlling bacterial growth, probably mediated through the actions of 
macrophages and pyroptosis. Immune-mediated pathology by hyper-production of pro-
inflammatory cytokines in BALB/c mice and excessive neutrophil recruitment to sites of 
infection probably leads to septic shock and mortality observed. 
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1.5 OBJECTIVES OF STUDY 
There is still much to elucidate what predisposes some humans to acute 
melioidosis, while others appear asymptomatic or develop chronic disease, when exposed 
to B. pseudomallei. Although animal models have been developed for the study of 
melioidosis, there are still many unanswered questions regarding the differential host 
susceptibility in mouse strains that could advance our understanding on differential host 
susceptibility to melioidosis in humans.   The overall aim of this study is to investigate 
the possible host factors contributing to melioidosis. The specific aims are: 
1) To determine whether IL-10, an anti-inflammatory cytokine, contributes to 
susceptibility to B. pseudomallei infection, and the cell types responsible for IL-
10 production during infection since susceptible BALB/c produce more IL-10 
during infection that resistant C57BL/6 mice. 
2) To determine whether reduced glutathione levels will contribute to susceptibility 
to B. pseudomallei infection in murine melioidosis, since a deficiency correlates 
to poor bacterial control in human diabetic patients. 
3) To identify what bacterial factors could affect the production of cytokines during 

















 B. pseudomallei infection results in varying outcomes, ranging from acute septic 
shock, chronic suppurative infection to asymptomatic infection. It is known that diabetes 
and renal disease are risk factors for developing melioidosis but not much is known about 
what contributes susceptibility to melioidosis. 
 To better understand the underlying risk factors that could contribute to 
susceptibility to melioidosis, inbred murine melioidosis models using BALB/c and 
C57BL/6 mice were developed (Leakey et al 1998). The BALB/c mice were more 
susceptible to B. pseudomallei infection compared to the relatively more resistant 
C57BL/6 mice. The C57BL/6 mice were able tolerate a bacterial inoculum 10 to 100 fold 
more than the BALB/c mice through various inoculation routes (Tan et al 2008). Limited 
genetic crosses carried out between the two mouse strains showed that there is a genetic 
basis for susceptibility, and this genetic basis appears to be on a single locus (Leakey et 
al 1998). However, genetic crosses involve many generations of mice and are time-
consuming and difficult to carry out.  
 An in vitro splenocyte infection model has been developed by our laboratory 
(Koo and Gan 2006) which exhibits similarities to what is observed by in vivo mouse 
infection with B. pseudomallei. In both in vitro and in vivo models, susceptible BALB/c 
mice produced more pro-inflammatory cytokines (e.g. IL-6, TNF-α and IFN-γ) compared 
to C57BL/6  mice, but yet had higher bacterial loads compared to the relatively resistant 
C57BL/6 (Ulett et al 2000, Liu et al, 2002, Koo and Gan 2006). BALB/c mice were 
found to produce more IL-10 than C57BL/6 mice in response to other pathogens like 
Mycobacterium avium (Rogue et al 2007), Chlamydia trachomatis (Yang et al 1996), 
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Brucella abortus (Baldwin and Parent 2002) and Trypanasoma congolense (Tabel et al 
1999). Depletion or knocking out of IL-10 leads to improved clearance of bacterial, 
protozoan and fungal pathogens such as Leishmania spp, Listeria monocytogenes, 
Mycobacterium spp and Yersinia spp (reviewed in Cyktor and Turner 2011). However, 
IL-10 is also required to dampen TNF-α mediated inflammation and mice lacking IL-10 
are susceptible to septic shock induced by TNF-α by the pathogens Plasmodium 
chabaudi, Trypanosoma gondii and T. cruzi (reviewed in Cyktor and Turner 2011). 
Hence, IL-10 can act as a double-edged sword, by limiting immunopathology while at the 
same time dampening inflammation which is important in microbial clearance. However, 
not much has been studied about the role of IL-10 in melioidosis, even though it is well-
known as an anti-inflammatory cytokine.  
In melioidosis patients, IL-6 and IL-10 are important predictors of mortality in 
melioidosis (Simpson et al 2000). Furthermore, serum free-derived bone marrow 
macrophages (BMMs) isolated from BALB/c mice produced more IL-10 than C57B/6 
BMMs in response to LPS stimulation (Eske et al 2009). On the other hand, in the last 
few years, new T-helper cell subsets have been discovered and characterised. One is the 
Th17 T-helper cell which is responsible for clearance of extracellular pathogens such as 
Klebsiella (Aujla et al 2008). This subset of T helper cells and the Th17 cytokines (such 
as IL-6, IL-22 and IL-23) have been found to be important in regulating neutrophil 
functions and production of anti-bacterial peptides (Ouyang et al 2008). However, the 
importance of Th17 cytokines in melioidosis, as well as the differences in levels of Th17 
cytokines between BALB/c and C57BL/6 mice has not been studied.  
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 In this study, we aim to use our in vitro splenocyte model to analyze differences 
in cytokine and chemokine production between the BALB/c and C57BL/6 mice. The role 
of IL-10 in B. pseudomallei infection, as well as the various cell types responsible for 




2.2 MATERIALS AND METHODS 
2.2.1 Mice 
 Female 6 to 8 week old C57BL/6 and BALB/c mice were purchased from the 
Laboratory Animals Center of the National University of Singapore. They were housed in 
cages with wood shavings, and fed a diet of commercial food pellets and potable water ad 
libitum. The mice were allowed to rest for at least 4 days before commencement of any 
experiment. All animal procedures are approved by the IACUC of NUS and DSO. 
2.2.2 Bacteria 
 Burkholderia pseudomallei strain KHW used in this study was isolated locally 
from a fatal case of melioidosis in Singapore (Liu et al 2002). Bacteria were cultured on 
Trypticase Soy Agar (TSA) (Difco Laboratories, Detroit, MI) for 24 h at 37oC. For 
infection of macrophages and splenocytes, colonies of B. pseudomallei were inoculated 
overnight in LB medium, before being diluted 1:20 and grown for 2.5 hours in 37oC with 
shaking to ensure bacteria were at mid-log phase of growth. Bacterial numbers were 
determined using a spectrophotometer (1 OD600 = 2 x 106 cfu/μl). For in vivo mouse 
infection experiments, bacteria were cultured on trypticase soy agar for 24 h at 37 °C. 
Colonies were resuspended in sterile PBS to an OD600 of 1.01 (equivalent to 1.07 x106 cfu. 
ml–1). The bacterial suspension was diluted to the desired concentrations for inoculation 
into mice and aliquots of these suspensions were plated on TSA in triplicates for 





2.2.3 Preparation and stimulation of splenocytes in vitro 
 Naïve mice were killed by carbon dioxide asphyxiation, and spleens were 
removed aseptically. Single cell suspensions of splenocytes were prepared by filtering 
through 40 μm sterile mesh and erythrocytes were lysed using ACK buffer (0.15M 
NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA). Splenocytes are plated in antibiotic-free 
complete RPMI 1640 medium (Sigma, St. Louis, MO) at a concentration of 5 x 106 cells 
per well in 12 well tissue culture plates, supplemented with 10% Fetal Bovine Serum 
(FBS) (Hyclone Laboratories, Logan, UT) and 200mM L-glutamine. Cells were infected 
with live B. pseudomallei at a multiplicity of infection (MOI) of 10:1. At 90 minutes after 
inoculation of B. pseudomallei, kanamycin was added to a final concentration of 
250μg/ml to kill off extracellular bacteria. Supernatants were harvested at indicated time 
points after infection, and stored at -20oC for ELISA whereas cells were centrifuged at 
500g X 5 minutes and lysed with Trizol reagent and stored at -80 oC.  
2.2.4 RNA isolation and real-time PCR 
 Total RNA was extracted using Trizol reagent and Purelink RNA isolation 
columns (Invitrogen, California), following the manufacturer’s instructions, and RNA 
resuspended in RNase free water. DNase treatment was carried out using the Turbo 
DNase Kit (Applied Biosystems, California) following manufacturer’s instructions, and 
RNA concentration was determined using the Nanodrop spectrophotometer (Thermo 
Fisher Scientific). Reverse transcription was carried out on the RNA samples using the 
High Capacity c-DNA Reverse Transcription Kit (Applied Biosystems, California). After 
that, real-time PCR was carried out on the cDNA obtained using Go Taq qPCR SYBR 
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green mix (Promega) following the manufacturer’s instructions. Various primer pairs 
listed below are used to amplify the genes on a 96-well plate.  
Primer Sequence 
MIP-2 Forward Primer AACATCCAGAGCTTGAGTGTGA 
MIP-2 Reverse Primer TTCAGGGTCAAGGCAAACTT 
IL-22 Forward Primer CATGCAGGAGGTGGTACCTT 
IL-22 Reverse Primer TCTGGATGTTCTGGTCGTCA 
IL-23p19 Forward Primer GCAGCTCTCTCGGAATCTCT 
IL-23p19 Reverse Primer TTGTGGGTCACAACCATCTT 
IFN-β Forward Primer ATGAGTGGTGGTTGCAGGC 
IFN-β Reverse Primer TGACCTTTCAAATGCAGTAGATTCA 
IFN-γ Forward Primer TCAAGTGGCATAGATGTGGAAGAA 
IFN-γ Reverse Primer TGGCTCTGCAGGATTTTCATG 
IL-10 Forward Primer GGTTGCCAAGCCTTATCGGA 
IL-10 Reverse Primer ACCTGCTCCACTGCCTTGCT 
IL-12p40 Forward Primer TGGTTTGCCATCGTTTTGCTG 
IL-12p40 Reverse Primer ACAGGTGAGGTTCACTGTTCCT 
IL-12p35 Forward Primer TTCTAGACAAGGGCATGCTG 
IL-12p35 Reverse Primer GCAGAGTCTCGCCATTATGA 
IL-6 Forward Primer CTGCAAGAGACTTCCATCCAGTT 
IL-6 Reverse Primer GAAGTAGGGAAGGCCGTGC 
TGF-β Forward Primer TGACGTCACTGGAGTTGTACGG 
TGF-β Reverse Primer GGTTCATGTCATGGATGGTGC 
Table 1: Primers used for real-time PCR for determination of chemokine and cytokine expression. 
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For bacterial gene expression, the following primers were used. 
Primer Sequence 
B. pseudomallei 16S Forward Primer GGCTAGTCTAACCGCAAGGA 
B. pseudomallei 16S Reverse Primer TCCGATACGGCTACCTTGTT 
bopE Forward Primer TCCTTCGCTTCGCTGAAGATCG 
bopE Reverse Primer ATTCGGCCGGCAAGTCTACG 
bsaN Forward Primer AATAAATCGGCGCTGGTTATCGGC 
bsaN Reverse Primer AGCAATTTCGCCGCCTCGAATAAC 
bsaM Forward Primer TGAAGCTCTGCAACTCCGAATC 
bsaM Reverse Primer AAATACTTCCCCTGAGGGAATCG 
Table 2: Primers used for real-time PCR for determination of T3SS3 gene expression. 
2.2.5 Determination of Cytokine Concentration by ELISA 
 Frozen supernatants from the mouse splenocytes were thawed at room 
temperature. Samples were assayed for IFN-γ and IL-10 using ELISA kits (Bender 
MedSystem, Austria) following the manufacturer’s instructions. Cell culture supernatants 
were diluted 2X and assayed in triplicates. The detection limits for these assays are 15.6 
pg/ ml for IFN-γ and 39 pg/ ml for IL-10.  
2.2.6 Intracellular Cytokine Staining 
 Splenocytes were infected with B. pseudomallei as described above. One hour 
after infection, kanamycin was added to a final concentration of 250μg/ml as well as  
GolgiStop (BD Biosciences, containing monesin), according to manufacturer’s 
instructions. 12 hours after infection, splenocytes were harvested by scraping and 
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centrifugation at 500g x 5 min before being washed once with FACS buffer (PBS, 2% 
heat-inactivated FBS, 2 mM EDTA). Surface staining was then carried out with the 
following antibodies: anti-CD3-FITC (17A2, rat IgG2b, Biolegend), anti-CD19-APC 
(6D5, rat IgG2a, Biolegend), anti-CD 49b-biotin (DX5, rat IgM, Biolegend), anti-F4/80-
biotin (BM8, IgG2a, Biolegend), anti-Ly6G-FITC (1A8, rat IgG2a, Biolegend) and 
Strepavidin-PerCP-Cy5.5 (BD Pharmigen).  
Intracellular cytokine staining was then carried out using the BD 
Cytofix/Cytoperm Fixation Permeabilization Kit (BD Biosciences) with the following 
antibodies: anti-IL-10-PE (JES5-16E3, rat IgG2b, Biolegend) and IgG2b-PE (RTK4530, 
Biolegend). After staining, cells were fixed in a final concentration of 2% 
paraformaldehyde before flow cytometry was carried out using FACSCanto II (Becton 
Dickinson, San Jose, CA) flow cytometer. Data were then analysed using FlowJo 
software.  
2.2.7 Preparation of bone marrow-derived-macrophages and in vitro infection 
 Naïve mice were killed by carbon dioxide asphyxiation, and tibias and femurs 
were removed aseptically. The ends of the tibias and femurs were snipped off and flushed 
with complete RMPI medium (Sigma, St. Louis, MO) supplemented with 10% Fetal 
Bovine Serum (FBS) (Hyclone Laboratories, Logan, UT), 200 mM L-glutamine, 100 
units/ml penicillin and 100 μg/ml streptomycin using a 2 ml syringe and 27G needle. 
Bone marrow stem cells were collected and centrifuged at 200g for 10 minutes, before 
being seeded onto 10 cm diameter petri dishes, and cultured for 7 days in complete RPMI 
medium with 10 ng/ml M-CSF, with changing of fresh medium every 2-3 days. On day 7, 
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bone marrow-derived macrophages (BMMs) (with purity of >90% by F4/80 staining and 
flow cytometry) were extracted by incubation with 1 mM EDTA pH 7.4 for 5-10 min at 
4oC followed by scraping using a cell scraper. After centrifugation at 500g X 5 min, the 
BMMs were seeded at 1x106 cells in 500 μl of complete RPMI medium in 24-well plates, 
and allowed to rest for 1 day before infection.  
 On day of infection, medium was replaced with fresh antibiotic-free RPMI 
medium and pre-treated with 2 μg/ml of anti-IL-10 or isotype control one hour before 
infection. The following antibodies were used for neutralization: anti-IL-10 (JES5-2A5, 
Biolegend) and Rat IgG1 (RTK2071, Biolegend) as isotype control. Infection was then 
carried out using log phase culture of B. pseudomallei KHW at a MOI of 1:1. After 
bacteria were added, the 24-well plate was then centrifuged at 500g X 5 min to allow 
bacteria to contact the cells. One hour after infection, kanamycin was added to a final 
concentration of 250 μg/ml to kill off extracellular bacteria. At 2 hour and 8 hour post-
infection, cells were washed 3 times with 1 ml of 1X PBS before lysing with 1 ml of 0.1% 
Triton-X in PBS. Serial dilution was carried out from the lysate, and plated onto TSA 
agar to obtain bacterial counts. Bacterial numbers were enumerated after incubating the 
LB agar plates at 37oC for 2 days. 
2.2.8 In vivo IL-10 neutralization and mouse infection 
  IL-10 neutralization was carried out by intra-peritoneal injection of 200 μg of 
anti-IL-10 (Clone JES5-2A5, Biolegend), Rat IgG1 (Clone RTK2071, Biolegend) as 
isotype control or PBS into groups of 8 mice each. Two hours after intra-peritoneal 
infection, 500 cfu of B. pseudomallei KHW was injected by the intra-peritoneal route into 
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each mouse from each group. An intra-peritoneal route of infection was chosen to mimic 
a systemic B. pseudomallei infection. The mice were observed daily for survival. 
2.2.9 In vitro IL-10 neutralization and infection of PBMCs 
  Peripheral blood mononuclear cells (PBMCs) were isolated from the blood by 
density gradient centrifugation using Histopaque 1077 (Sigma). Following cell separation, 
PBMCs were recovered and washed twice with 1 x PBS and resuspended in antibiotics- 
free RPMI 1640 (Gibco) supplemented with 10% heat-inactivated fetal bovine serum 
(Gibco). Pre-treatment with 1μg/ml anti-IL-10 antibody (Clone JES3-9D7, Biolegend) 
and rat IgG1 (Clone RTK2071, Biolegend) as isotype control was carried out 1 hour 
before infection with log phase B. pseudomallei KHW at a MOI of 10:1.  After addition 
of bacteria, the 24-well plate was centrifuged at 500g for 5 min, to allow bacteria to 
contact the cells. After 2 hours of infection, kanamycin was added to a final concentration 
of 250 μg/ml to kill off extracellular bacteria. At 16 hours after infection, cells were 
collected from individual wells by centrifuging at 500g for 5 min and the cell pellet was 
lysed with 0.1% Triton-X in PBS to release intracellular bacteria. Serial dilution was 
carried out on the lysate before plating on LB agar plates. Bacterial numbers were 
enumerated after incubating the LB agar plates at 37oC for 2 days. 
2.2.10 Statistical analysis 
Statistical analysis was carried out using the Student’s t-test for unpaired samples. 





2.3.1 Differential regulation of cytokine genes between BALB/c and Infected 
C57BL/6 splenocytes 
To understand whether there are differences in cytokine gene transcripts upon 
infection of the splenocytes between the two strains of mice, RNA was extracted from 
Burkholderia pseudomallei-infected splenocytes (at an MOI of 10:1) from BALB/c and 








Fig. 1: Real-time PCR of selected cytokine genes from infected splenocytes at various time points. 
Splenocytes were infected with B. pseudomallei at MOI of 10:1, and harvested at various time points 
before RNA isolation was carried out for reverse transcription and real-time PCR. This experiment was 
performed twice. 
Figure 1 shows that MIP-2, IL-22, IL-23 (which shares the same p40 subunit as 
IL-12) and IFN-β were upregulated more in infected C57BL/6 splenocytes compared to 
infected BALB/c splenocytes. IL-23 and IFN-β were upregulated early in C57BL/6 
splenocytes at 4 hours, but declined dramatically at later time points. However IL-10 and 




















IFN-γ transcript levels were upregulated more in Infected BALB/c splenocytes compared 
to Infected C57BL/6 splenocytes, with the IFN-γ fold change reaching a peak at 4 hours 
while IL-10 transcripts reached a peak much later at 8 hours. Other key cytokines such as 
IL-6 and TGF-β did not appear to show any differences between the infected BALB/c 
and infected C57BL/6 splenocytes. We decided to focus on IL-10 and IFN- γ as these key 
cytokines play an important role in macrophage activation and both were also produced 
in BALB/c infection in vivo at much higher levels than infected C57BL/6 mice (Ulett et 
al 2000). 
2.3.2 Time course kinetics of IL-10 and IFN-γ secretion in infected splenocytes  
 Previously, we found that there is hyper-production of IFN-γ in infected BALB/c 
mice, correlating with higher bacterial loads with in vivo intranasal infection, at day 1 
post infection. From our real-time PCR screening on our in vitro splenocyte model, we 
observed an increased production of IL-10 transcripts in BALB/c-derived splenocytes 
compared to C57BL/6-derived splenocytes. IL-10 is a known anti-inflammatory cytokine, 
and can suppress macrophage activation, leading to reduced microbicidal activity. This 
may then lead to higher bacterial loads which would result in the hyper-inflammation 
seen in in vivo infection of BALB/c mice. As transcript levels may not necessarily be 
correlated to protein levels, we carried out a time course of ELISA experiments using our 

















Fig 2: ELISA from supernatants of infected splenocytes at various time points. Splenocytes were 
infected at MOI 10:1 and supernatants from infected wells collected by centrifuging at 13600g for 3 
minutes. (A) IL-10 ELISA (B) IFN-γ ELISA. This experiment was performed twice. 
 
In Figs 2A and 2B, we can see that IL-10 secretion was induced 4-6 hours earlier 
than IFN-γ in our in vitro splenocyte infection model. This result was also observed in 
infected human PBMCs (Peripheral Blood Mononuclear Cells) (unpublished results by 
our laboratory). 
The levels of IL-10 and IFN- γ from infected BALB/c splenocytes were also 





splenocytes were induced at an earlier timepoint as compared to infected C57BL/6 
splenocytes.  
2.3.3 Cell types responsible for IL-10 production in BALB/c and C57BL/6 
splenocytes 
To see if the differences in IL-10 production between the BALB/c and C57BL/6 
splenocytes in our in vitro model are due to specific immune cells, intracellular cytokine 
staining was carried out, using antibodies against various cell surface antigens specific to 




















Fig. 3: Intracellular cytokine staining of splenocytes from BALB/c mice. Splenocytes were infected 
with B. pseudomallei for 1 hour and then treated with monesin for 11 hours before harvesting. Splenocytes 
were surfaced stained for A) CD3 (T cells) B) CD19 (B cells) C) Ly6G (neutrophils) D) F4/80 
(macrophages) and E) CD49b (NK cells) before being stained intracellularly for IL-10. This experiment 

























































Fig. 4: Intracellular cytokine staining of splenocytes from C57BL/6 mice. Splenocytes were infected 
with B. pseudomallei for 1 hour and then treated with monesin for 11 hours before harvesting. Splenocytes 
were surfaced stained for A) CD3 (T cells) B) CD19 (B cells) C) Ly6G (neutrophils) D) F4/80 
(macrophages) and E) CD49b (NK cells) before being stained intracellularly for IL-10. This experiment 










Figures 3 and 4 show that the major producers of IL-10 in both BALB/c and 
C57BL/6 strains of mice were mainly the macrophages and the NK cells, which 
constitute the innate immune system. This early production of IL-10 could potentially 
suppress macrophage activity as IL-10 can lead to the deactivation of macrophages. IL-
10 has been known to suppress pro-inflammatory cytokine production by macrophages, 
downregulate MHC Class II expression, and suppress the release of nitric oxide. 
(reviewed in Gordon 2003). 
2.3.4 In vitro neutralisation of IL-10 in bone marrow-derived macrophages 
As macrophages are one of the major target cells of IL-10, which are down 
regulated by this cytokine and they themselves also produce IL-10, we wanted to 
determine whether in vitro neutralization of IL-10 in bone marrow-derived macrophages 
(BMMs) would exert a protective effect. To do this, we generated BMMs and infected 
them with B. pseudomallei, and measured intracellular counts at various time points. We 
found that IL-10 neutralization had a beneficial effect in terms of intracellular bacterial 
killing in both BALB/c and C57BL/c derived BMMs (Figs 5A and B). However, the 
intracellular bacterial counts were reduced by a greater degree upon IL-10 neutralization 
in BALB/c BMMs as compared to C57BL/6 BMMs (about 30% reduction in IL-10 




































































Fig. 5: Intracellular bacterial counts in BMMs. BMMs were cultured for up to a week before they were 
infected with B. pseudomallei KHW at a MOI of 1:1 for 2 or 10 hours. A) Infected BALB/c BMMs either 
untreated, treated with anti-IL-10 or its isotype control. B) Infected C57BL/6 BMMs either untreated, 
treated with anti-IL-10 or its isotype control. . *p < 0.01,   **p < 0.001. This experiment was performed 
thrice. Purity of macrophages measured using flow cytometry C) BALB/c BMMs stained with isotype 
control and PerCP D) BALB/c BMMS stained with F4/80 and PerCP E) C57BL/6 BMMs stained with 
isotype control and PerCP F) C57BL/6 BMMS stained with F4/80 and PerCP G) IL-10 production kinetics 








2.3.5 Expression of bacterial virulence gene cluster T3SS3 in splenocytes 
 Besides looking at differences in host cytokine and chemokine gene expression, 
we were interested to determine whether there is differential expression of bacterial 
virulence genes between BALB/c and C57BL/6 derived splenocytes infected with 
bacteria. The T3SS3 in B. pseudomallei is one of the important virulence gene clusters in 
B. pseudomallei, and is divided into 3 operons, with the T3SS3 components bsaN, bsaM 
and bopE in each of these operons. There were no significant differences in expression of 
T3SS3 genes between the BALB/c and C57BL/6 splenocytes at various time-points (Figs 


















Fig 6: Bacterial gene expression of the 3 T3SS3 operons in BALB/c and C57BL/6 derived splenocytes. 
Splenocytes were infected at a MOI of 10:1 and lysed with Trizol reagent before reverse transcription and 
real-time PCR. Real-time expression of the T3SS3 clusters at (A) 4 hours and (B) 8 hours after infection. 
This experiment was performed thrice. The fold changes were normalised to Infected BALB/c splenocytes. 
2.3.6 In vivo neutralisation of IL-10 in BALB/c mice 
Since we observed that in vitro neutralisation has a beneficial effect on reducing 
bacterial loads inside macrophages, one of the key cells of the innate immune system, we 
asked if we could improve survival in infected mice in vivo. We treated the relatively 
more susceptible BALB/c mice by intra-peritoneal injection of either PBS, anti-IL-10 or 
its isotype control, and then infected them intraperitoneally with B. pseudomallei. An 
intra-peritoneal route of infection was chosen to mimic the systemic infection seen in 












Fig. 7: Survival curve of BALB/c mice. Three groups of 8 mice each were treated with anti-IL-10 
antibody, isotype control (200 ug) or PBS 2 hours before i.p infection with 500 cfu of B. pseudomallei. 
Survival of the mice was monitored daily for 3 weeks.  NS: Not statistically significant. 
 Contrary to what we expected, in vivo neutralization of IL-10 in susceptible 
BALB/c mice had no protective effect compared to the PBS-treated and isotype-treated 
control groups (Fig 7). In fact from days 7 to 11, more of the anti-IL-10 treated mice died 
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as compared to the isotype treated control group. The intraperitoneal dose used was half 
the LD50 dose of B. pseudomallei in BALB/c mice (Tan et al 2008). We also observed 
that after 9 days of infection when about half or more of the mice had died, the disease 
started to progress into a chronic phase, marked by formation of abscesses in the 
peritoneal cavity. No mice recovered from the chronic phase of the disease, and all 
eventually died or were about to die when the experiment was terminated. 
2.3.7 In vitro neutralisation of IL-10 in PBMCs 
To see if we could recapitulate the results of our in vitro BMM infection in a 
human system, we enumerated bacterial loads in human PBMCs after infection with B. 
pseudomallei KHW, with or without IL-10 neutralisation. Results showed no difference 
in bacterial loads in human PBMCs with or without treatment with anti-IL-10 antibody 








Fig. 8: Intracellular bacterial loads in PBMCs. PBMCs were pre-treated with anti IL-10 or its isotype  
control (IgG2b) for 1 hour before infection with B. pseudomallei KHW at a MOI of 10:1 for 16 hours. 
PBMCs are then centrifuged down and lysed with 0.1%Triton-X before serially diluting the lysate, plating 




 In this study, we aim to delineate the differences between the susceptible BALB/c 
and the relatively more resistant C57BL/6 using an in vitro splenocyte model that our 
laboratory has developed to simulate in vivo infection of mice (Koo and Gan 2006). Our 
initial screening showed that C57BL/6 splenocytes induced more MIP-2, IL-22 and IL-23. 
MIP-2, also known as CXCL2, is an important chemokine responsible for the recruitment 
of neutrophils to the sites of infection (reviewed in Kobayashi 2006), and may possibly 
explain why C57BL/6 mice are relatively more resistant since neutrophils play an 
important role in the killing of bacterial pathogens. Bancroft et al (2007) documented the 
importance of neutrophils in B. pseudomallei infection. The roles of IL-22 and IL-23 
have not been well-studied in B. pseudomallei infection. However, IL-22 has been shown 
to be responsible for controlling other pathogens like Citrobacter and Klebsiella (Zheng 
et al 2008, Aujla et al 2008). It does this by upregulating host defense genes such as 
lipocalin, calgranulins, β-defensins and C-type lectins. On the other hand, IL-23 is part of 
the Th17-IL-23 pathway, and is also responsible for the recruitment of neutrophils and 
the production of MIP-2 (Godinez et al 2009). Although the Th17-IL23 pathway is 
generally known for its activity against extracellular bacteria, IL-23 deficiency has been 
implicated in poor control of intracellular pathogens like Mycoplasma pneumoniae (Wu 
et al 2007), Listeria monocytogenes (Meeks et al 2009) and Salmonella typhimurum 
(Godinez et al 2009). Thus, the increased transcription of IL-23 by infected C57BL/6 
splenocytes compared to infected BALB/c splenocytes may be one possible reason why 
C57BL/6 are relatively more resistant to B. pseudomallei infection. However, due to the 
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constraints of this study, we did not explore these three cytokines any further. Instead, we 
further examined the IL-10 and IFN- γ responses in our in vitro splenocyte model. 
In our model, we observed that IL-10 and IFN- γ transcripts in infected BALB/c 
splenocytes were more upregulated compared to infected C57BL/6 splenocytes. These 
results mirrored those seen in the in vivo infection model (Ulett et al 2000) where 
transcripts of IL-10 and IFN-γ were higher in the livers and spleens of infected BALB/c 
mice compared to C57BL/6 mice. Besides transcript levels, we observed the same 
phenotype with protein levels using ELISA. We noticed that IL-10 was induced earlier 
than IFN- γ in our splenocyte model and that infected BALB/c splenocytes produce more 
IL-10 as compared to infected C57BL/6 splenocytes.  This result suggests that early 
production of IL-10 may be one of the reasons why BALB/c mice are susceptible to 
Burkholderia pseudomallei infection. This is because IL-10 can down-regulate 
macrophage activation by inhibiting the production of reactive oxygen and nitrogen 
intermediates which macrophages use to kill ingested bacteria (reviewed in Moore et al 
1993). Such macrophages are known as alternatively activated macrophages (M2). Thus, 
IL-10 may be a cause of defective bacterial control in susceptible BALB/c mice rather 
than a consequence to elicit negative feedback on IFN-γ production. With a defective 
bacterial control due to the action of IL-10, the high bacterial loads in BALB/c mice 
would then result in hyper-inflammation and immune pathology. To characterize the cell 
types responsible for IL-10 production, we carried out intracellular staining. We found 
macrophages and NK cells to be the major cell types contributing to IL-10 production, 
instead of T-cells. It has been shown that IL-10 is generally produced by macrophages in 
response to intracellular pathogens such as Chlamydia trachomatis (Ohman et al 2006).  
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Recently, it was documented that NK cells produce IL-10 in response to systemic 
infections induced by intracellular pathogens such as Toxoplasma gondii and Listeria 
monocytogenes (Perona-Wright et al 2009). This IL-10 production was due to early IL-12 
produced by dendritic cells during systemic infection, and serves in turn to negatively 
regulate IL-12 production. .Grant et al (2008) has documented the production of IL-10 by 
NK cells in vitro, which required IL-2 or IL-12. On the other hand, T-cells are not the 
major producers of IL-10 in our model, in contrast to other documented studies where 
Th1, Th2, Th17 and Treg cells were shown to produce IL-10 (reviewed in Saraiva and 
O’Garra 2010). This shows that the early production of IL-10 in our in vitro model is 
contributed mainly by cells of the innate immune system instead of the adaptive immune 
system. Previously, it was found that in B. pseudomallei infection, IFN-γ was found to be 
produced dominantly by NK cells, with contributions by T-cells and NK T cells (Koo and 
Gan 2006, Hague et al 2006). In this study, we found that NK cells are also responsible 
for the early production of IL-10. It could be that the same NK cells make both IL-10 and 
IFN-γ as in the case of Grant et al (2008) and that the production of these two cytokines 
differs in a temporal manner. Another scenario may be that different subsets of NK cells 
are each responsible for the production of IL-10 or IFN- γ.  
To test the hypothesis that IL-10 may be detrimental in control of B. pseudomallei, 
we used BMMs generated by differentiating bone marrow stem cells with monocyte-
colony stimulating factor (M-CSF) for a week. After in vitro IL-10 neutralization and 
infection with B. pseudomallei, we compared the bacterial loads at various time points 
between BALB/c derived BMMs and C57BL/6 derived BMMs. IL-10 neutralisation has 
a positive effect in reducing intracellular bacteria loads within BMMs. BALB/c BMMs 
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showed a greater decrease in bacterial loads compared to C57BL/c BMMs. However, 
even after IL-10 neutralisation, the BALB/c BMMs still contained higher bacterial loads 
at 8 hours after infection compared to C57BL/6 BMMs. This may reflect intrinsic 
differences in bactericidal mechanisms between the two strains of mice that are 
independent of IL-10. In fact, naïve C57BL/6 BMMs without IFN-γ priming had lower 
intracellular bacterial loads compared with counterpart BALB/c BMMs, showing that 
there are some intrinsic IFN-γ independent mechanisms present in C57BL/6 (Breitbach et 
al 2006).  
 Various in vivo models have documented the importance of IL-10 in the infection 
process. IL-10 has been shown to play an important role in Yersinia pseudotuberculosis 
infection as susceptible BALB/c mice generate more IL-10 compared to resistant 
C57BL/6 mice, and thus produce M2 macrophages that utilize arginase instead of iNOS , 
leading to macrophages that do not generate reactive nitrogen species to kill bacteria and 
are less microbicidal (Tansini and de Medeiros 2009). IL-10 deficient mice are also 
resistant to infection with Yersinia pestis (Turner et al 2009) and Listeria monocytogenes 
(Dai et al 1997). However, in our in vivo mouse model, we were unable to show that IL-
10 depletion has a protective effect. This may be due to the complex effects of IL-10 on 
melioidosis since besides down-regulating macrophage activation; it also suppresses the 
immune system by negatively regulating pro-inflammatory cytokines such as IFN-γ, 
TNF-α, IL-1β (Howard et al 1993). In acute melioidosis, patients generally die due to 
septic shock. However, the immunology of sepsis is quite complex, with some studies 
showing a bi-phasic response, characterised by an initial pro-inflammatory phase where 
excessive production of pro-inflammatory cytokines is due to overwhelming bacterial 
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infection in the body followed by a compensatory anti-inflammatory phase characterised 
by the production of anti-inflammatory cytokines like IL-10, leading to macrophage 
deactivation (Kox et al 2000). It may be that IL-10 neutralisation may have a beneficial 
effect in vivo in BALB/c mice but the side effect of neutralising IL-10 is hyper-
production of pro-inflammatory cytokines, leading to shock and death. Alternatively, it 
could be that neutralisation of IL-10 is incomplete or that IL-10 does not contribute to 
pathogenesis in melioidosis, which is what was found for other pathogens such as 
Salmonella typhimurum (Pie et al 1996). In PBMCs, we also did not observe a protective 
effect with neutralising IL-10 alone. Therefore, other mechanisms may compensate for 
the depletion of IL-10, or IL-10 may not play a role in acute melioidosis in humans. 
However, it could possibly play a role in the persistence of B. pseudomallei in chronic 
melioidosis in humans, as in the case of latent tuberculosis infection (Gong et al 1996). 
 In conclusion, we observed that MIP-2, IL-22 and IL-23 are upregulated at the 
transcript level in infected C57BL/6 splenocytes, whereas IFN-γ and IL-10 transcripts as 
well as protein levels are much higher in infected BALB/c splenocytes in our in vitro 
model. Cell types responsible for production of IL-10 in both mice are generally from the 
innate immune system, i.e. macrophages and NK cells. In vitro neutralization of IL-10 
was observed to exhibit a beneficial effect in reducing bacterial load in bone marrow-
derived macrophages from both strains of mice, with BALB/c BMMs showing a greater 
reduction in bacterial load after IL-10 neutralisation. However, in vivo neutralization does 
not seem to have a protective effect in infected BALB/c mice. The mechanisms by which 
















3.1  INTRODUCTION 
 One of the major risk factors for developing melioidosis is Type 2 diabetes. The 
proportion of melioidosis patients with Type 2 diabetes is about 39% in Top End 
Australia, 59% in Cambodia, 57% in Kedah, Malaysia, 68% in Southern India, 47.9% in 
Singapore, and 46.5% in Northeastern Thailand (Hassan et al 2010, Vlighe et al 2011, 
Currie et al 2010, Saravu et al 2010, Lo et al 2009, Limmathurotsakul et al 2010). In 
contrast to Type 2 diabetes, the number of melioidosis patients with Type 1 diabetes is 
less than 10%, showing that Type 1 diabetes is not a significant risk factor for developing 
melioidosis (Simpson et al 2003). With such a high association between Type 2 diabetes 
and melioidosis in endemic areas, it is of interest to delineate the possible mechanisms by 
which Type 2 diabetes leads to increased susceptibility to melioidosis. 
 Polymorphonuclear neutrophils from diabetics exhibit reduced IL-8 mediated 
chemotaxis, apoptosis and phagocytosis (Chanchamroen et al 2009). Other studies on the 
association of diabetes and melioidosis have utilised animal models of streptozocin-
induced Type 1 diabetes, which is not really relevant to what is found in human patients. 
However, the recent Type 2 diabetic mouse model may provide insights on why Type 2 
diabetes is a risk factor (Hodgson et al 2011). In that mouse model, it was found that 
Type 2 diabetic mice succumbed to B. pseudomallei infection within 4 days compared to 
10 days with the normal mice. It was also found that the macrophages in the Type 2 
diabetic mice are impaired in intracellular killing of B. pseudomallei, with reduced 
production of bactericidal nitric oxide. 
 Besides being a major risk factor for melioidosis, Type 2 diabetes also increases 
the risk of acquiring other infections such as tuberculosis, pneumonia, skin infections, 
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urinary tract infections and candidiasis, showing that the defect in immune responses is  
particular to several pathogens (Peleg et al 2007, Muller et al 2005). 
 Our previous studies have shown that peripheral blood mononuclear cells 
(PBMCs) from Type 2 diabetics have a reduced production of IFN-γ and IL-12 in 
response to B. pseudomallei and Mycobacterium tuberculosis (Tan et al 2012). This 
defect in IFN-γ and IL-12 production was subsequently found to be due to a deficiency in 
intracellular reduced glutathione (GSH) levels in Type 2 diabetics.  
 In this study, we aim to develop an in vivo mouse model of GSH depletion to 
determine whether GSH deficiency could pre-dispose the host to acute disease. This 
model may be a representation of what is observed in Type 2 diabetes in terms of how 




3.2 MATERIALS AND METHODS 
3.2.1 Mice 
 Female 8 to 10 week old BALB/c mice were purchased from the Laboratory 
Animals Centre of the National University of Singapore. They were housed in cages with 
wood shavings, and fed a diet of commercial food pellets and potable water ad libitum. 
The mice were allowed to rest for at least 4 days before commencement of any 
experiment. All animal procedures are approved by the IACUC of NUS and DSO. 
3.2.2 Bacteria 
 Burkholderia pseudomallei strain KHW used in this study was isolated locally 
from a fatal case of melioidosis in Singapore (Liu et al 2002). For in vivo mouse infection 
experiments, bacteria were cultured on trypticase soy agar for 24 h at 37 °C. Colonies 
were resuspended in sterile PBS to an OD600 of 1.01 (equivalent to 1x106 cfu μl–1). The 
bacterial suspension was diluted to the desired concentrations for inoculation into 
mice,and aliquots of these suspensions were plated on TSA in triplicates for retrospective 
determination of the number of viable bacteria inoculated into the mice. 
3.2.3 In vivo GSH supplementation and depletion in mice 
 For GSH depletion experiments, mice were grouped into untreated as well as 
diethyl maleate (DEM) and buthionine sulfoximine (BSO) treatment groups. DEM was 
used to deplete the intracellular pool of GSH, whereas BSO was used concurrently to 
inhibit further synthesis of reduced GSH. Mice were matched by weight from both 
groups, and GSH depletion was carried out by administering DEM (Sigma) (0.8 mL/kg) 
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and BSO (Sigma) (700 mg/kg) to mice 2 hours prior to infection by intra-peritoneal 
injection.  
 For GSH supplementation, N-acetyl-cysteine (NAC) was used. 2 mg/ml of NAC 
was added to drinking water for the mice to drink 4 days prior to infection. The NAC-
treated water was changed every 3 days until the termination of the experiment. As NAC 
solution is quite acidic (pH ~ 2-3), 1N sodium hydroxide was added to neutralise this 
solution to about pH 7.0 before giving it to the mice to drink. 
3.2.4 Mice infection for survival studies 
 After GSH depletion was carried out, mice were infected by the intra-peritoneal 
route with 2000 cfu of B. pseudomallei KHW strain. For GSH supplementation using 
NAC, 1000 cfu of B. pseudomallei was administered to the mice via the intra-peritoneal 
route. The mice were observed daily, mortality was scored and plotted into a Kaplan-
Meier survival curve and mortality of untreated mice was compared to treated mice.  
3.2.5 Bacterial load determination in spleen 
 For bacterial load determination, mice were grouped into two groups: untreated 
and DEM/BSO treated with 12-18 mice each. Mice were infected by the intra-peritoneal 
route with ~1000 (990-12000) cfu of B. pseudomallei KHW. At time points of 24 and 48 
hours, 4-6 mice from each group were sacrificed by carbon dioxide asphyxiation and 
their spleens harvested. The spleens were homogenized in 2 ml of 1X PBS, using the 
back of the syringe on top of 70 μm cell strainers (BD Falcon, San Diego, California). 
The spleen homogenates were then appropriately diluted, and plated in duplicate on 
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Ashdown agar. Colonies were enumerated after 36 hours of incubation in a 37oC bacterial 
incubator. 
3.2.6 Cytokine Determination 
 Spleen homogenates were filtered through 0.22 μm filters (Millipore, 
Massachusetts) to ensure sterility and stored at -80oC. The following ELISA kits were 
used to determine cytokine concentrations: mouse IL-1β, IFN-γ, TNF-α and IL-12 
(Biolegend), following the manufacturers’ instructions. The detection limits for these 
assays were: 15.6 ng/ml for mouse IFN-γ, 7.8 ng/ml for IL-12 and TNF-α, and 31.3 
ng/ml for mouse IL-1β. 
3.2.7 Preparation of splenocytes for in vitro infection. 
 Mice were sacrificed by carbon dioxide asphyxiation and spleens harvested 
aseptically. The spleens were homogenized and treated with 1 mg/ml collagenase D 
(Roche Diagnostics, Mannheim, Germany) for 1 hour to extract dendritic cells. The cell 
suspension was then passed through a 40 um sterile mesh, and erythrocytes were lysed 
using ACK buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA). Splenocytes 
were plated in antibiotic-free complete RPMI 1640 medium (Sigma, St. Louis, MO) at a 
concentration of 5 x 106 cells/ well in 12-well tissue culture plates, supplemented with 10% 
Fetal Bovine Serum (FBS) (Hyclone Laboratories, Logan, UT), 200 mM L-glutamine. 
For DEM pre-treatment, splenocytes were pre-treated with 50 μM DEM for 2 hours 
before infection. For IFN-γ co-treatment, splenocytes were treated with 1000 Units/ml of 
IFN-γ while being infected with B. pseudomallei KHW. For both treatments, the DEM 
and IFN-γ were not washed off upon infection with B. pseudomallei. Cells were infected 
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with live B. pseudomallei at a MOI of 5:1. At 2 hours after inoculation of B. 
pseudomallei, kanamycin was added to a final concentration of 250 μg/ml to kill off 
extracellular bacteria. Supernatants were collected from each well after 36 hours of 
infection for ELISA. 
3.2.8 Surface staining  
 Splenocytes were scraped off wells and washed with FACS buffer before being 
treated with Fc-receptor blocking reagent (10 ul per 107 cells) (Miltenyi Biotec) for 10 
minutes. Splenocytes were then stained for the appropriate cell surface markers: anti-
CD19-APC (Clone 6D5, Biolegend), anti-F480-APC (Clone BM8, Biolegend), anti-CD3-
FITC (Clone 145-2C11, BD Pharmingen), anti-I-A/I-E-FITC (Clone M5/114.15.2, 
Biolegend) and anti-CD11c-APC (Clone N418, Miltenyi Biotec) for 30 minutes before 
being washed with FACS buffer twice. Cells were then fixed in 1% paraformaldehyde in 
FACS buffer before flow cytometry was carried using a BD FACS CantoII flow 
cytometer. Data were analysed using the FlowJo software.  
3.2.8 Intracellular cytokine staining   
 IFN-γ treated splenocytes were treated with BD GolgiPlug (BD Pharmingen) after 
12 hours of infection. At 24 hours after infection, surface staining was carried out 
according to the previous section. Instead of fixing in 1% paraformaldehyde, cells are 
now fixed and permeabilised with the BD Cytofix/Cytoperm Kit (BD Pharmingen), 
following the manufacturer’s instructions. The following antibodies from Biolegend were 
used for intracellular cytokine staining after permeabilization: anti-IL-12 p40-PE (Clone 
C15.6) and IgG1-PE (Clone RTK2071) as isotype control. After intracellular staining, 
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cells were fixed in 1% paraformaldehyde and flow cytometry was carried using a BD 
LSRFortessa flow cytometer. Data were then analysed using the FlowJo software.  
3.2.9 Statistical analysis  
Statistical analysis was carried out using the Student’s t-test for unpaired samples. 
A p value of <0.05 is regarded as statistically significant. 






3.3.1 Glutathione depletion increases susceptibility of BALB/c mice to B. 
pseudomallei infection 
 To examine whether glutathione deficiency would increase the susceptibility of 
BALB/c mice to B. pseudomallei infection, DEM/BSO treatment was carried out to 
deplete intracellular GSH in mice before infection was carried out. Results showed that in 
GSH-depleted mice, they died twice as early compared to the untreated group after both 






Fig. 9: Effect of GSH depletion on survival of mice after infection with B. pseudomallei. Six mice per 
group were used and DEM/BSO was administered intra-peritoneally 2 hours prior to infection with B. 







3.3.2 Glutathione supplementation does not decrease susceptibility of BALB/c 
mice to B. pseudomallei infection 
 Since GSH depletion increases susceptibility of BALB/c mice to B. pseudomallei, 
we sought to determine if the reverse were true. However, GSH supplementation through 
adding NAC in the drinking water of the mice did not apparently improve the disease 
outcome (Fig. 10). 
 
Fig. 10: Effect of NAC supplementation on survival of mice after infection with B. pseudomallei. Six 
mice per group were used and NAC was through drinking water 4 days prior to infection with B. 
pseudomallei. Survival was monitored daily for 18 days. 
 
3.3.3 Glutathione depletion increases organ loads in spleens of BALB/c mice 
 In an effort to understand the mechanisms by which glutathione depletion renders 
BALB/c mice more susceptible to B. pseudomallei infection, spleens of infected mice 
were homogenised at various timpoints and organ loads determined by plating on 
Ashdown’s agar using appropriate dilutions.  Results showed that GSH depletion through 
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DEM/BSO treatment significantly reduced the ability of the mice to restrict bacterial 
loads in the spleens as compared to the untreated group (Fig. 11). 
 
Fig. 11: Effect of GSH depletion on bacterial loads in infected mice. Four to six mice per group were 
sacrificed at 1 or 2 days after infection, and spleens homogenised and plated at appropriate dilutions. *p < 
0.05, *** p < 0.001. 
 
3.3.4 Glutathione depletion affects production of IL-12 in BALB/c mice 
 Since GSH depletion increased organ loads in mice, we wanted to determine the 
possible mechanisms which could lead to poorer bacterial control in GSH-depleted mice. 
The cytokines IL-12 and IFN-γ are important in the control of intracellular pathogens and 
we were interested to see if GSH depletion has any effect on these two cytokines, which 
was what we found with human PBMCs (Tan et al 2012). Figure 12 shows decreased IL-
12 concentration at two days post-infection in GSH-depleted mice compared to untreated 
mice. However, there was an increase in the other cytokines like IFN-γ, IL-1β and TNF-α 
at 24 hours after infection in the GSH-depleted group compared to the untreated group. 
There was also a decrease in the levels of IL-12, IFN-γ and TNF-α from day 1 and 2 




Fig. 12: Effect of GSH depletion on cytokine levels in BALB/c spleens. Four to six mice per group were 
sacrificed at 1 or 2 days after infection, and spleens homogenised and ELISAs carried out for the following 
cytokines. (A) IL-12 (B) IFN-γ (C) IL-1β (D) TNF-α. *p < 0.05, *** p < 0.001. 
 
3.3.5  Glutathione depletion affects production of IL-12 and IFN-γ but not TNF-α 
in BALB/c splenocytes 
As the high bacterial loads in the mice could lead to hyper-inflammation and 
mask the effect of GSH depletion on IFN-γ, we sought to simplify the system by using 
our in vitro splenocyte model.  Results from that model showed that IFN-γ production 
was totally abolished upon GSH depletion, showing that GSH affects production of IFN-





13B) was not affected by GSH depletion, showing that GSH selectively modulates the 
cytokines IFN-γ and IL-12. Due to the detection limits of the ELISA kit, we were unable 





Fig. 13: Effect of GSH depletion on cytokine levels in in vitro splenocyte infection. Splenocytes were 
pre-treated with 50 μM of DEM for 2 hours before being infected with B. pseudomallei KHW at a MOI of 
5:1 for 36 hours. Supernatants were then collected and ELISAs carried out. A) IFN-γ B) TNF-α. N.S: not 
statiscally significant. This experiment was performed thrice. 
 To boost the production of IL-12 to detection levels, we co-primed the 
splenocytes with IFNγ while infecting them with B. pseudomallei strain KHW. We found 
that GSH depletion also affects IL-12 production from primed splenocytes (Figure 14). 
 
Fig. 14: Effect of GSH depletion on IL-12 in in vitro splenocyte infection. Splenocytes were pre-treated 
with 50 μM of DEM for 2 hours before being infected with B. pseudomallei KHW at MOI of 5:1 and co-
treated with 1000 units/ml of IFN-γ, for 36 hours. Supernatants were then collected and IL-12 ELISA 




3.3.6  Glutathione depletion does not selectively deplete certain cell types. 
To ascertain that the selective depletion of cytokines upon GSH depletion is not 
cell-specific, surface staining and flow cytometry were carried out to compare the 
populations of various major leukocyte cell types. Figs. 15-18 (summarised on Table 3) 
show that there was no selective depletion of any leukocyte cell type. This indicates that 
GSH depletion probably acts at the level of intracellular cell signalling level to affect 



















Fig. 15: Surface staining of B-cell populations in splenocytes. Splenocytes were stained for CD19 and 
flow cytometry carried out. A) Uninfected splenocytes B) 0 μM DEM treatment + B. pseudomallei 





















Fig. 16: Surface staining of macrophage populations in splenocytes. Splenocytes were stained for F4/80 
and flow cytometry carried out. A) Uninfected splenocytes B) 0 μM DEM treatment + B. pseudomallei 



































Fig. 17: Surface staining of T-cell populations in splenocytes. Splenocytes were stained for CD3 and 
flow cytometry carried out. A) Uninfected splenocytes B) 0 μM DEM treatment + B. pseudomallei 

























Fig. 18: Surface staining of dendritic cell populations in splenocytes. Splenocytes were doubly stained 
for CD11c and MHC Class II (I-A/I-E) and flow cytometry carried out. Dendritic cells are CD11c positive 
and MHC Class II positive A) Uninfected splenocytes B) 0 μM DEM treatment + B. pseudomallei infection 













Cell Type Uninfected (%) 0 μM DEM + KHW 
(%) 
50 μM DEM + 
KHW (%) 
APC Control for 
CD19 and F480 
0.32% 0.78% 0.52% 
B cells (CD19 ) 44.6 – 0.32 = 44.28% 50.5 – 0.78 = 49.72% 47.5 – 0.52 = 
46.98% 
Macrophages (F480)  2.89 – 0.32 = 2.57% 2.40 – 0.78 = 1.62% 2.57 – 0.52 = 2.05% 
T cells (CD3) 49.6% 49.5% 47% 
DCs (CD11c and 
MHCII) 
1.66% 1.67% 1.77% 
Table 3: Summary of surface staining of splenocytes. An Isotype control (IgG2a-APC) was used to gate 
out B cells and macrophages and subtracted from final calculation. This experiment was performed twice. 
 
3.3.6  Dendritic cells are major producers of IL-12 in B. pseudomallei infection. 
 To find out what cell types are responsible for producing IL-12 in mice, we 
carried out intracellular staining on splenocytes by surface staining them. It is known that 
macrophages and dendritic cells are major producers of IL-12 during infection, hence 
cells are surface stained for markers to these cell types. Results suggest that macrophages 
are not the major producers of IL-12, as the IL-12 producing cells were not brightly 
stained for PE (Figs. 19A-B). This is in contrast to DC cells (Figs. 19 C-D), i.e. the 
CD11c positive cells are IL-12 PE-bright as well. As there is a right-ward shift in PE-
positive populations when anti-IL-12 PE-positive cells is compared to its isotype control, 
we decided to compare between uninfected and infected cells, using anti-IL-12 PE (Figs. 
19E to H). Results show that there was a major shift in IL-12 positive cells (40% in 
uninfected versus 60% in infected), indicating that DCs are the cells responsible for 
































Fig. 19: Intracellular staining of IL-12positive cells in splenocytes. Splenocytes were treated with 
Brefeldin A 12 hours before harvesting and surface-stained before carrying out intracellular staining. A) 
Infected splenocytes stained for F480 (macrophage marker) and isotype control. B) Infected splenocytes 
stained for F480 (macrophage marker) and anti-IL-12. C) Infected splenocytes stained for CD11c (DC 
marker) and isotype control. D) Infected splenocytes stained for CD11c (DC marker) and anti-IL-12. All 
DCs are found to be MHCII positive. E) Uninfected splenocytes stained for CD11c and MHCII (DC 
marker) and anti-IL-12.  F) Infected splenocytes stained for CD11c and MHCII (DC marker) and anti-IL-
12 G) DC marker positive cells from (E) gated for anti-IL-12.  H) DC marker positive cells from (F) gated 








From our results, we can conclude that glutathione deficiency contributes to 
decreased survival in mice in vivo. In vitro, this may be attributed to the decrease in 
production of the cytokines IL-12 and IFN-γ which is important in the control of 
intracellular pathogens. In vivo, we observed higher levels of IFN-γ, IL-1β and TNF-α on 
DEM/BSO treated mice compared to untreated mice on day one after infection. This 
paradox could be explained by the fact that the DEM/BSO treated mice failed to contain 
bacterial replication in the initial stages of the infection, leading to higher bacterial loads 
and hyper-inflammation. This previously demonstrated hyper-inflammation (Liu et al 
2002) masked the effects of glutathione depletion on the cytokines IL-12 and IFN-γ. The 
higher bacterial loads may result from an early depletion of IFN-γ and IL-12, which are 
important in controlling the growth of intracellular bacteria like B. pseudomallei in the 
DEM/BSO-treated mice which exhibited deficiency in reduced glutathione. On day 2, we 
could observe the effects of glutathione depletion on IL-12 which was decreased in the 
DEM/BSO-treated mice, whereas for IFN-γ, the same trend was observed with IFN-γ 
decreased in the DEM/BSO treated mice, although it did not reach statistical significance. 
This could mean that glutathione itself could have IL-12/IFN-γ independent bactericidal 
mechanisms in the early phases of the infection, while at later stages of infection, 
glutathione plays other roles like inducing IL-12 to control bacterial growth. Another 
scenario may be the hyper-inflammation observed in the early phases of infection 
mayhave been resolved by day 2, allowing us to observe the effects of glutathione 
depletion on IL-12 and IFN-γ production in mice. 
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It has been demonstrated in Taylor Outbred mice that IFN-γ neutralization renders 
the mice more susceptible to B. pseudomallei infection, as seen by the reduction of the 
LD50 from > 5 X 105 cfu to 2 cfu (Santanirand et al 1999). It has also been demonstrated 
that IL-12 is important in the induction of IFN-γ, and that IL-12 knockout C57BL/6 mice 
succumbed more rapidly to B. pseudomallei infection, from 30 days in wild-type mice to 
4 days in IL-12 or IFN- γ knockout mice (Hague et al 2006). These findings, coupled 
with our observation that glutathione depletion by the administration of DEM/BSO 
increases bacterial loads in spleens with concurrent reduction in IL-12 and IFN- γ levels 
indicate that the glutathione deficiency is directly linked to susceptibility to melioidosis.  
The NAC treatment to boost GSH levels in BALB/c mice did not increase 
resistance to B. pseudomallei infection. This may be due to the fact that the levels of GSH 
in BALB/c mice may already be at the optimum level, and the addition of NAC does not 
increase GSH levels. In fact, high NAC concentrations have been shown to act as a pro-
oxidant instead of an anti-oxidant, and reduce the GSH/GSSG ratio in rats as well as in 
human subjects (Harvey et al 2008, Kleinveld et al 1992). High NAC concentrations 
have also been found to increase the expression of calmodulin which in turn sequesters c-
Rel in the cytoplasm (Alam et al 2010). c-Rel is known to be an important transcription 
factor regulating the production of IL-12, and thus the sequestration of c-Rel will in turn 
inhibit IL-12 production (Rahim et al 2005).  
Our laboratory has shown that in Type 2 diabetic patients, their PBMCs had lower 
GSH levels compared to healthy controls, thus contributing to decreased IL-12 and IFN- 
γ production and leading to higher intracellular bacterial loads in vitro (Tan et al 2012, in 
press). This may be due to the excess glucose entering the sorbitol pathway and depleting 
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NADPH which is required for conversion of oxidized glutathione (GSSG) back to 
reduced glutathione (GSH) (Chung et al 2003).  
Our mouse infection model was able to recapitulate what is observed with in vitro 
human PBMCs. Given the fact that dendritic cells are the major producers of IL-12 in B. 
pseudomallei infection, suitable adjuvants and priming strategies may be used to boost 
IL-12 production in susceptible people, especially those with underlying risk factors.  
Besides Type 2 diabetes mellitus being a well-known risk factor for developing 
melioidosis, other risk factors include: chronic renal failure, thalassemia and chronic 
alcohol consumption (Currie 2003, Suputtamongkol et al 1999). Chronic renal failure 
patients are in a chronic state of oxidative stress and have GSH deficiency, independently 
of whether they undergo dialysis or not (Ceballos-Picot et al 1996, Annuk et al 2001). 
This is attributed to the kidney being one of the major organs that synthesizes anti-
oxidant enzymes, and renal failure decreases the production of such enzymes (Demirci et 
al 2011). The dialysis procedure that is used in the management of renal failure also 
exacerbates the oxidative stress and glutathione deficiency in these patients (Nguyen-
Khoa et al 2001). This is due to the loss of vitamin C, trace elements and regulatory 
enzymes during the dialysis procedure (Mekki et al 2010). Besides increased oxidative 
stress which reduces the amount of reduced GSH, renal failure and dialysis patients also 
have reduced expression of γ-glutamylcysteine synthetase, a key enzyme in the rate-
limiting step of de novo generation of GSH (Alhamdani 2005).  Taken together with our 
observation that glutathione deficiency results in poor control of B. pseudomallei, this 
may explain why chronic renal failure is a risk factor for developing melioidosis, in 
addition to diabetes.  
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 Thalassemia is another risk factor characterized by the deficiency of either the 
beta or alpha globin chains of haemoglobin. As a result of this deficiency, the 
haemoglobin that is formed is unstable, precipitates, and then degrades to form free heme 
and iron (Rachmilewitz et al 2005, Rund and Rachmilewitz 2005, Shinar and 
Rachmilewitz 1990). Free, non-heme bound iron is a strong pro-oxidant, and cangenerate 
free radicals via the Fenton reaction as follows: 
 
As GSH is a major anti-oxidant in the human body, GSH levels are greatly decreased in 
thalassemia patients as it is depleted to mop up the hydroxyl free radicals generated by 
the iron overload (Rund and Rachmilewitz 2005, Chakraborty et al 2010). Thus, taken 
with our results, one reason why thalassemia is a risk factor in developing melioidosis 
may be glutathione deficiency in thalassemia patients. Other possible reasons may be the 
splenomegaly due to the rapid clearance of defective erythrocytes in thalassemia patients. 
Splenectomies carried out in some thalassemia patients may render them immuno-
compromised as the spleen is a major immune organ in the body (Sakran et al 2011). 
 Lastly, chronic alcohol consumption is a risk factor for developing melioidosis. 
The metabolism of alcohol in the human body is primarily through the actions of alcohol 
dehydrogenase and the microsomal ethanol oxidation system that utilizes the CYP2E1 
enzyme (Zima et al 2001).  The action of alcohol dehydrogenase produces acetaldehyde 
which can form free radicals if not converted to acetyl-CoA by the enzyme aldehyde 
dehydrogenase. Acetaldehyde can form an adduct with GSH, thus leading to deficiency 
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in GSH levels (Tsukamoto and Lu 2001, Cederbaum et al 2009). Ethanol can also inhibit 
glutathione synthesis in the liver by decreasing the influx of cysteine, one of the three 
amino acids required for glutathione synthesis (Lauterberg et al 1984). 
Taken together, these risk factors have a common unifying theme i.e. chronic 
deficiency of reduced glutathione due to various mechanisms (Fig. 20). This may 
possibly explain why patients with these risk factors are at an increased risk of 
developing melioidosis since reduced glutathione levels reduces IFN-γ in the early phases 
of infection, leading to poorer control of intracellular bacteria. 
 
Fig. 20: Unifying theme behind various risk factors of melioidosis. Various risk factors of melioidosis 
are known to deplete intracellular GSH levels. As GSH regulates IL-12 production, which in turn regulates 
IFN-γ production, this could provide a logical explanation for why people with these risk factors are 












MODULATION OF HOST CYTOKINE 
RESPONSES BY THE BURKHOLDERIA 
PSEUDOMALLEI PROTEIN BIPB 
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4.1  INTRODUCTION 
 The immune system presents a formidable obstacle to invading pathogens 
wishing to gain a foothold inside the host and cause disease. To circumvent this defensive 
system, numerous strategies have been evolved by pathogens throughout their mutual co-
evolution with the hosts they reside in. Some of these strategies involve resistance to 
phagocytosis, secretion of toxins, reducing antigen presentation, modulating the immune 
system to an immune-suppressive phenotype, and various other mechanisms (reviewed in 
Hornef et al 2002).  
One of the important classes of regulators of the innate and adaptive immune 
systems is the cytokines which mediate activation and suppression of the immune system. 
The adaptive immune system could be also switched between a Th2 phenotype which 
favors production of antibodies to kill extracellular pathogens, to a Th1 phenotype which 
favors the activation of killer T cells and macrophages to kill intracellular pathogens. It is 
therefore of no surprise that pathogens could modulate the levels of key cytokines in the 
human body to elicit a desirable outcome for the pathogen. 
Degradation of cytokines is one example by which bacteria could regulate the 
levels of these key chemical messengers. Pseudomonas aeroginosa, a bacterium 
responsible for many nosocomial infections, secretes an alkaline protease to break down 
IL-2, TNF-α and IFN-γ (Horvat and Parmely 1998, Parmely et al 1990).  Legionella 
pneumophila secretes a zinc metalloprotease that cleaves IL-2 which is necessary to 
induce T-cell proliferation (Mintz et al 1993). 
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Another mechanism by which bacteria can reduce the levels of cytokines is to 
directly affect the synthesis or secretion of cytokines from cells. Cholera toxin by Vibrio 
cholerae and anthrax edema toxin produced by Bacillus anthracis can affect intracellular 
cAMP levels and reduce the subsequent production of TNF-α, a key pro-inflammatory 
cytokine (Leal-Berumen et al 1996, Hoover et al 1994). The T3SS protein, YopB in 
Yersinia enterocolitica can inhibit secretion of TNF-α in Peyer’s patches (Beuscher et al 
1995). In Bordetella, the T3SS effector BopN has been found to inhibit the translocation 
of NFκB p65 subunit into the nucleus and increases the production of IL-10, an anti-
inflammatory cytokine to suppress the host immune system (Nagamatsu et al 2009). 
B. pseudomallei possesses numerous mechanisms to subvert the various host 
cytokine production and signaling mechanisms. Firstly, B. pseudomallei could activate 
negative regulators of cytokine signaling, sterile-α and Armadillo motif (SARM)-
containing protein as well as suppressor of cytokine signalling (SOCS3) molecules 
(Pudia et al 2011, Ekchariyawat et al 2005). SARM upregulation leads to reduced IFN-β 
and inducible nitric oxide synthase (iNOS) production, and reduces bacterial killing in 
macrophages. On the other hand, SOCS3 inhibits IFN-γ signalling to downregulate iNOS 
and activation of macrophages, leading to diminished bacterial killing. B. pseudomallei 
also secretes TssM, a deubiquitinase which suppresses the NF-κB and ISRE pathways, 
leading to reduced production of  TNF-α and IFN-β in infected RAW 264.7 cells (Tan et 
al 2010). 
As mentioned in the Introduction, the T3SS3 of B. pseudomallei is an important 
virulence factor in animal infection (Fig. 21). The T3SS3 consists of BsaL and BsaK 
which makes up the needle, BsaM and BsaJ which constitute the inner membrane ring 
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and BsaQWXYZ which form the base of the needle complex. The secretion of T3SS3 
effectors is controlled by the translocon complex consisting of BipB, BipC and BipD. 
The transcriptional regulation of the T3SS3 is governed by the proteins BicA and BsaN 
(Sun et al 2010). 
 
In this study, which arose out of our work on IL-10, we describe a B. 







Fig 21: The T3SS3 of B. pseudomallei. The T3SS3 consists of a needle as well as chaperone, effectors and 
a base of the needle. (Reproduced from Sun and Gan 2010). 
 Some of the effectors of the T3SS3 system have been characterized. BopE was 
found to be a guanine nucleotide exchange factor that interacts with Cdc42 (Upadhyay et 
al 2008). BopA was found to suppress autophagy and escape from the phagosome (Gong 
et al 2011).  
In this study, which arose out of our work on IL-10, we describe a B. 
pseudomallei T3SS3 protein BipB that affects the production of many cytokines.  
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4.2  MATERIALS AND METHODS 
4.2.1 Bacterial strains and plasmids 
 Burkholderia pseudomallei strain KHW used in this study was isolated locally 
from a fatal case of melioidosis in Singapore (Liu et al 2002). Various mutants were 
derived from this wildtype stain of B. pseudomallei, and are listed in Table 4. For 
infection purposes, bacteria were grown overnight and on the day of infection, a mid-log 
phase culture was prepared by diluting the overnight stock 1:20 into LB broth, and grown 
for 2.5-3 hours. 
Bacterial strains Description Source or reference 
E. coli 
DH5α Cloning host. Sambrook et al 1989 
SM10 Donor strain for conjugation. Simon et al 1983 
B. pseudomallei 
KHW B. pseudomallei wildtype strain, Gmr. Liu et al 2002 
KHWΔT3SS1 BPSS1386-1411 region was replaced 
with tet cassette, TetR, KmS. 
Lee et al 2010 
KHWΔT3SS2 BPSS1592-1629 region was replaced 
with tet cassette, TetR, KmS. 
Lee et al 2010 
KHWΔT3SS3 BPSS1520-1552 region was replaced 
with zeo cassette, ZeoR, KmS. 
Lee et al 2010 
ΔbsaN KHW ΔbsaN::FRT, BPSS1546 was 
deleted. 
Sun et al 2010 
ΔbsaM KHW ΔbsaN::FRT, BPSS1546 was 
deleted. 
Chen YH (unpublished) 
ΔbipB KHW Δbip::FRT, BPSS1532 was 
deleted. 
Teh BE (unpublished) 
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ΔbipB-t KHW ΔbipB:: Ωkm-2, mini Himar-1 
cassette inserted in the middle of 
 BPSS1532. Transposon mutant. 
Sun GW (unpublished) 
ΔbsaM-t KHW ΔbsaM:: Ωkm-2, mini Himar-1 
cassette inserted in the middle of 
 BPSS1547. Transposon mutant. 
Sun GW (unpublished) 
ΔbsaS-t KHW ΔbsaM:: Ωkm-2, mini Himar-1 
cassette inserted in the middle of 
 BPSS1541. Transposon mutant. 
Sun GW (unpublished) 
ΔbsaV-t KHW ΔbsaM:: Ωkm-2, mini Himar-1 
cassette inserted in the middle of 
 BPSS1538. Transposon mutant. 
Sun GW (unpublished) 
Plasmids   
pUCP pUCP28T. For overexpression of 
bacterial proteins. 
West et al 1994 
pUCP-bipB pUCP28T contains bipB orf and 
upstream sequence from KHW, Tmr. 
This work 
pGEM-bipB pGEM-T easy plasmid with bipB 
inserted by TA cloning. 
Teh BE (unpublished) 
Table 4: Bacterial strains and plasmids used in this work 
4.2.2 Cell Lines 
Murine macrophage cell line RAW 264.7 and human embryonic kidney 
HEK293T cells were cultured in DMEM medium (Sigma, St. Louis, MO) with 10 % 
heat-inactivated FBS (Biological Industries, Israel), 2 mM L-glutamine (Sigma), 100 
U/ml penicillin and 0.1 mg/ml streptomycin (Sigma). Human monocytic cell line U937 
was cultured in RPMI medium (Sigma, St. Louis, MO) with 10 % heat-inactivated FBS 
(Biological Industries, Israel), 2 mM L-glutamine (Sigma), 100 U/ml penicillin and 0.1 
mg/ml streptomycin (Sigma). All cells were passaged every 2-3 days. 
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4.2.3 Construction of pUCP-BipB 
pUCP28T was digested with EcoRI, and TSAP (Promega, 37oC for 2 hours) was 
used to prevent religation of the plasmid backbone. pGEM-T-bipB containing the bipB 
gene was digested with EcoRI and gel purified. The digested pUCP28T and bipB DNA 
fragments were then ligated together using T4 DNA Ligase (Promega, room temperature 
for 5 hours), and transformation carried out into E. coli DH5α cells by electroporation 
(section 4.2.4). The transformed E. coli cells were plated onto LB agar plates containing 
trimethoprim (30 μg/ml), X-Gal (20 mg/ml) and IPTG (20 mg/ml). White colonies were 
picked, and colony PCR (section 4.2.5) carried out to ascertain the presence of bipB. 
Positive clones were sent for DNA sequencing (1st Base) for verification. 
4.2.4 Preparation of competent cells and electroporation 
 E. coli SM10 and DH5α were grown overnight in liquid yeast extract nutrient 
broth (YENB, Difco laboratories). Electrocompetent cells are prepared using the protocol 
by Sharma & Schimke (1996). 5-10 ml of overnight E. coli culture was inoculated onto 1 
L of YENB medium, and grown at 37oC with shaking, and cells were harvested when 
OD600 reached 0.5-0.9. The cells were centrifuged at 4000g X 10 minutes at 4oC, and 
washed twice in 100 ml of cold water, and 20 ml of cold 10% glycerol. Finally, the cells 
were resuspended in 2-3 ml of cold 10% glycerol, and aliquoted into Eppendorf tubes at 
40 uL per tube.  
For electroporation, electro-competent E. coli cells were thawed on ice, and 100 
ng of ligated product or 50 ng of purified plasmid was added to the thawed cells. These 
cells were then transferred to a 0.2 cm electroporation cuvette (Bio-Rad) and 
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electroporated using a Gene Pulser® (Bio-Rad). After electroporation, 1 ml of LB 
medium was added to the cells, which were left in a 37oC incubator for 2 hours to recover. 
The cells were then plated on LB agar plates containing the appropriate antibiotics for 
selection. 
4.2.5 Colony PCR 
 For selection of positive clones, colony PCR was carried out. Individual colonies 
were picked up on a pipette tip and added into a PCR mix (for 8 reactions): 
GoTaq Green Master Mix (Promega) : 100 ul 
DMSO     : 10 ul 
BipB Forward Primer (100 uM) : 2 ul 
BipB Reverse Primer (100 uM) : 2 ul 
Nuclease free water   : 86 ul 
 
The primers used were: 
BipB Forward: CATATGATGTCATCCGGAGTGCAC 
BipB Reverse: TCTAGACACTGCGCCGGCGTTACG 
 
The cycling conditions used were: 
94oC for 4 minutes followed by 35 cycles of (94oC for 30 seconds, 58oC for 30 seconds 
and 72oC for 1 minute) and finally 72oC for 5 minutes before holding at 4oC. 
4.2.6 Generation of B. pseudomallei over-expression mutants  
 Plasmids generated from section 4.2.3 and 4.2.4 were transformed into E. coli 
SM10 strain by electroporation. E. coli SM10 donor strain and B. pseudomallei KHW 
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recipient strain, were grown overnight in LB, with trimethoprim added to E. coli donor 
culture for maintenance of plasmid. On the next day, E. coli was centrifuged down at 
maximum speed for 3 minutes and resuspended in antibiotic free LB. The E. coli donor 
and B. pseudomallei acceptor were mixed at a ratio of 1:1 in a final volume of 100 μl, 
plated on a LB agar plate with a sterile cellulose nitrate filter disk (Diameter: 47 mm, 
pore size: 0.45 μm, Sartorius), and grown for three hours in 37oC. After that, the sterile 
filter disk was transferred onto a LB agar plate containing trimethoprim (60 μg/ml) and 
gentamicin (25 μg/ml) to kill off donor E. coli. Successful conjugants were transferred 
onto a fresh LB plate with - (60 μg/ml). 
4.2.7 Infection of cell lines 
U937 cells were seeded in 24-well plates at a density of 0.5 million/well, with 10 
ng/ml of PMA in RPMI medium to differentiate them for 2 days. On day of infection, 
culture medium was changed to fresh RPMI medium, without antibiotics 2 hours prior to 
infection. After infection at MOI of 10:1, the plates were centrifuged at 500g X 5 minutes 
to allow bacteria to contact the cells. One hour after infection, the culture medium was 
replaced by fresh culture medium containing 10 μg/ml imipenem, with 2 mM 
cytochalasin D to completely block bacterial intake into cells. This method reduces 
cytotoxicity to insignificant levels as it reduces bacterial loads inside cells.  
RAW cells were seeded at 0.5 million/well in 24-well plates in DMEM and 
incubated overnight. Two hours before infection, the culture medium of RAW cells was 
changed to RPMI without any antibiotics, and cells were infected at a MOI of 100:1, with 
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centrifugation to contact cells. After 2 hours of infection, the infection medium as 
changed to RPMI with kanamycin (250 μg/ml) to kill off extracellular bacteria.  
HEK293T cells were seeded at 1 million/well in 12 well-plates in DMEM and 
incubated overnight. Two hours before infection, the culture medium of HEK293T cells 
was changed to DMEM without any antibiotics, and cells were infected at an MOI of 
100:1, with centrifugation to contact cells. After two hours of infection, the infection 
medium was changed to DMEM with kanamycin (250 μg/ml) to kill off extracellular 
bacteria.  
All cells are grown in a 37oC cell culture incubator, with 5% CO2. 
4.2.8 Determination of cytokine production 
 Frozen supernatants from the infected cell lines were thawed at room temperature. 
Samples were assayed for human IL-10, IL-8, TNF-α (Biolegend) and IL-6 (BenderMed 
Systems) using ELISA kits following the manufacturer’s instructions. Cell culture 
supernatants were diluted and assayed in triplicates. The detection limits for these assays 
is 3.9 pg/ml for IL-10, 7.8 pg/ml for TNF-α, 1.6 pg/ml for IL-6 and 15.6 pg/ml for IL-8. 
For Multianalyte ELISA Inflammatory Cytokine panel (SA Biosciences), the 
frozen supernatants were thawed at room temperature and the assay carried out, 
following the manufacturer’s instructions. 
4.2.9 RNA isolation and real-time PCR 
 RAW 264.7 cells were washed twice with PBS, total RNA was extracted using 
Trizol reagent and Purelink RNA isolation columns (Invitrogen, California), following 
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the manufacturer’s instructions, and RNA resuspended in RNase free water. DNase 
treatment was carried out using the Turbo DNase Kit (Applied Biosystems, California) 
following manufacturer’s instructions, and RNA concentration was determined using the 
Nanodrop spectrophotometer (Thermo Fisher Scientific). Reverse transcription was 
carried out on the RNA samples using the High Capacity c-DNA Reverse Transcription 
Kit (Applied Biosystems, California). Real-time PCR was carried out using Go Taq 
qPCR SYBR green mix (Promega) following the manufacturer’s instructions with the 
following primer pair. 
iNOSf: CAGCTGGGCTGTACAAACCTT 
iNOSr: CATTGGAAGTGAAGCGTTTCG 
4.2.10 In vitro infection of primary human monocytes and differentiation 
  Peripheral blood mononuclear cells (PBMCs) were isolated from the blood by 
density gradient centrifugation using Histopaque 1077 (Sigma). Following cell separation, 
monocytes are extracted using CD14 microbeads (Miltenyi Biotec) and MACS separator 
following the manufacturer’s instructions. 
 Monocytes were differentiated into macrophages using human recombinant M-
CSF (Peprotech). They were grown in RPMI medium with M-CSF (200 ng/ml) for 7 
days, with change of medium at days 3 and 5 to new RPMI medium with M-CSF (200 
ng/ml). 
 For infection, B. pseudomallei was added to a MOI of 10:1 to wells containing 
monocytes or macrophages, centrifuged at 500g X 5 minutes. 1 hour after infection, 
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kanamycin was added to a final concentration of 250μg/ml. 12 hours after infection, 
supernatants from each well were collected for IL-10 quantification. 
 
4.2.11 Statistical analysis 
Statistical analysis was carried out using the Student’s t-test for unpaired samples. 






4.3.1 T3SS3 is required to inhibit IL-10 production  
 To investigate the possible mechanisms that B. pseudomallei induces IL-10 
production, we examined whether there was any difference between wild-type B. 
pseudomallei and its T3SS mutants. To our surprise, we found that the T3SS3 mutant 
exhibited an increased IL-10 production compared to the wildtype (Fig. 21), showing that 
this virulence cluster could modulate cytokine production. In contrast, T3SS1 and T3SS2 
had no effect on IL-10 production, consistent with their roles in plant infection. The 
T3SS3 cluster of B. pseudomallei has an opposite function to that of Bordetella which is 






Fig. 22: T3SS3 cluster is required to suppress IL-10 production. PMA differentiated U937 cells were 
infected with wild-type B. pseudomallei (KHW) or its Type III secretion system mutants, ΔT3SS1, ΔT3SS2 
or ΔT3SS3 for 8 hours before supernatant was collected for IL-10 ELISA. **p<0.01. 
 
4.3.2 BipB, a translocon protein is required to inhibit IL-10 production 
To find out which component of the T3SS3 is essential for inhibition of IL-10 
production, we examined a panel of various T3SS3 mutants. Results show that any of the 
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T3SS3 components could be the factor responsible for B. pseudomallei mediated IL-10 
suppression (Fig. 23). BsaN was previously found to be a transcriptional regulator of the 
T3SS3 (Sun et al 2010), and its deletion will reduce T3SS3 effector expression, whereas 
BsaM, BsaS and BsaV are structural components of the base of the T3SS3 complex and 
deletion of these components will result in no needle complex being formed and no 
secretion of T3SS3 effectors. SipB and IpaB, the homologues of B. pseudomallei BipB 
were found to be important in regulating the secretion of T3SS3 effectors, and in the 
absence of them, there is hypersecretion of T3SS effectors (Ménard et al 1994). 
Previously, one of our laboratory members showed that in HEK293T co-transfection with 
NF-κB SEAP reporter and constructs with various T3SS3 proteins, only BipB was able to 
inhibit NF-κB activation (Teh BE unpublished data). Hence, we decided to see if BipB 







Fig. 23: BipB could be the candidate required to suppress IL-10 production. PMA differentiated U937 
cells were infected with wild-type B. pseudomallei (KHW) or T3SS3 mutants for 8 hours before 
supernatant was collected for IL-10 ELISA.  ΔbipB-t is a T3SS3 translocon mutant, while ΔbsaN is a 
transcriptional regulator mutant and ΔbsaM-t, ΔbsaS-t and ΔbsaV-t are various structural mutants of the 




4.3.3 BipB is an inhibitor of multiple cytokine secretion 
To find out whether BipB could inhibit the production of multiple cytokines, we 
tested a panel of cytokines using the Multi-analyte ELISA Inflammatory Cytokine panel 
(SA Biosciences) and verified the results using ELISA (Fig. 24). Results show that the 
BipB mutant exhibited increased production of the cytokines IL-6, while not affecting the 
production of other cytokines such as IL-1α, IL-1β and IL-12 (Fig. 24A). However, as the 
sensitivity of the assay is lower than that of an ELISA, the differences observed with IL-
10 were not significant with this assay even though we have already demonstrated that 
BipB affects IL-10 production. Therefore, for ELISA verification purposes (Figs 24B and 



















Fig. 24: BipB is an inhibitor of multiple cytokine production. PMA differentiated U937 cells were 
infected with wild-type B. pseudomallei (KHW) or ΔbipB-t for 8 hours before supernatants were collected 
for A) Multi-analyte ELISA and results of multi-analyte ELISA are verified by B) IL-6 ELISA and C) 
TNF-α ELISA. *p < 0.05, **p < 0.01.  For (a) the differences in other cytokines were not significant. This 
experiment was performed twice for parts b and c. 
4.3.4 BipB requires entry into cells to elicit its effects on cytokine production 
As Chen et al (2011) has shown that B. pseudomallei T3SS3 only requires cell 
contact for it to be activated, we wanted to find out whether BipB requires entry into the 
macrophages to elicit its suppressive effects on cytokine production. Using cytochalasin 
D to block bacterial entry into the cells, we found that bacterial entry is required to inhibit 










Fig. 25: BipB requires bacterial entry into cells to elicit its effects. PMA differentiated U937 cells were 
pre-treated 1 hour before infection with or without cytochalasin D to block bacterial entry into cells. After 8 
hours of infection with wildtype KHW or ΔbipB-t, without antibiotics added, supernatants were collected 
for A) IL-10 ELISA B) IL-6 ELISA or C) TNF-α ELISA. This experiment was performed twice. **p < 





4.3.5 The cytokine inhibitory effects of BipB are neither due to polar mutations 
nor through secretory defects.  
 As our ΔbipB-t mutant is a transposon mutant, the inhibitory effects of BipB that 
we observed could be due to a polar mutation as the BipB operon also contains genes 
such as bipC, bprA and bipD (Suparak et al 2005), and the effects we observed could be 
due to these other genes. To verify that the results observed were due to the action of 
BipB alone, we carried out a two-pronged approach through the use of a “clean deletion” 
BipB mutant, and the use of wildtype B. pseudomallei over-expressing BipB. Results 
show that the clean deletion mutant, ΔbipB exhibits the same phenotype as the transposon 
mutant, ΔbipB-t in that the ΔbipB mutant has an increased production of the cytokines IL-
6, IL-10 and TNF-α (Fig. 26). Besides possible polar effects due to the use of transposon 
mutants, the bipB mutant also exhibits multiple defects like hyper-secretion of T3SS3 
effectors (Sun GW, unpublished data). To further confirm that the effects of cytokine 
suppression observed, we generated BipB-overexpressing B. pseudomallei KHW. Over-
expression of BipB in wild-type B. pseudomallei KHW decreased the production of 
cytokines compared to B. pseudomallei KHW transformed with empty vector pUCP. This 
























Fig. 26: Effects of BipB is not due to polar mutation. PMA differentiated U937 cells were infected with 
wild-type B. pseudomallei (KHW) or ΔbipB for 8 hours before supernatants were collected for A) IL-10 
ELISA B) IL-6 ELISA or C) TNF-α ELISA. U937 cells were also infected with B. pseudomallei 
transformed with empty pUCP vector or pUCP-BipB and supernatants collected for D) IL-10 E) IL-6 
ELISA or F) TNF-α ELISA. . *p < 0.05 **p < 0.01. These experiments were performed twice. 
 
4.3.6 BipB interferes with IL-8 production in HEK cells 
 Since we found that BipB is an inhibitor of multiple cytokines in differentiated 
monocytes, we wondered if the case is true for epithelial cells. To do so, we infected 
HEK293T cells, a human epithelial cell line with wild-type KHW overexpressing BipB. 
This was done instead of using the B. pseudomallei BipB mutant as we previously found 





of IL-8 (Hii et al 2008). Results show that cells infected with the BipB overexpressing B. 
pseudomallei resulted in a decreased production of IL-8 compared to those infected with 








Fig. 27: BipB inhibits IL-8 secretion in HEK cells. HEK293T cells were infected with either KHW 
transformed with empty vector pUCP or pUCP-BipB and infected for 16 hours before supernatants were 
collected for IL-8 ELISA. This experiment was performed twice. ***p < 0.001.  
 
4.3.7 BipB interferes with iNOS induction in RAW264.7 macrophages  
 Inducible nitric oxide synthase is an important microbicidal mechanism against B. 
pseudomallei in BALB/c mouse (Breitbach et al 2011). In contrast to mouse 
macrophages, human macrophages generally do not produce much iNOS and reactive 
nitrogen species as a result (Schneemann et al 1993). Therefore, to study the effects of 
BipB on iNOS induction, we changed to a murine macrophage cell line RAW264.7. 
When infected with KHW overexpressing BipB, iNOS induction was reduced 4-fold in 










Fig. 28: BipB inhibits iNOS production in RAW macrophages. RAW264.7 cells were infected with 
either KHW transformed with empty vector pUCP or pUCP-BipB and infected for 6 hours before cells 
were lysed with Trizol reagent for real-time PCR. This experiment was performed twice. *p < 0.05 
 
4.3.8 The suppression of cytokine production is dependent on 
monocyte/macrophage differentiation status 
 To determine whether suppression of cytokines is affected by cell differentiation 
status, we infected primary monocytes with and without treatment with recombinant M-
CSF as well as the use of undifferentiated U937 cells. Results show that without 
differentiation, both primary monocytes as well as U937 cell lines showed only a slight 
difference between infection with wildtype B. pseudomallei KHW or T3SS3 mutant (Fig. 
29). For undifferentiated U937 cells (Fig. 29A), even with an infection of up to30 hours, 
we observed only a 10% difference in IL-10 production between wildtype and the T3SS3 
mutant. We observed the same phenomenon with primary human monocytes, with a 
greater difference observed between wildtype KHW infected cells versus T3SS3 mutant 

























Fig. 29: Differentiation status of monocyte/macrophage affects differences in IL-10 suppression by 
T3SS3. A) Undifferentiated U937 cells were infected with B. pseudomallei for 36 hours and supernatant 
collected for IL-10 ELISA. B) Primary human monocytes from two volunteers (H64 and D05) were 
collected and either differentiated or undifferentiated with recombinant human M-CSF and infected with B. 









Our results show that BipB is a novel inhibitor of pro-inflammatory cytokines 
such as IL-6 and TNFα. It also downregulates iNOS, which is critical in generating 
reactive nitrogen species to kill B. pseudomallei in mice (Brietbach et al 2011). The 
pathway by which BipB causes its inhibitory effects is not delineated yet although studies 
by our laboratory suggested that this could be through the inhibition of NF-κB, a central 
regulator of inflammation (Teh BE unpublished data). It is known that NF-κB can 
regulate the synthesis of IL-6 and IL-8 through synergistic action with CEBPB (also 
known as NF-IL6 previously, Matsusaka et al 1993), and that there are NF-κB promoter 
sites on the TNFα gene (Liu et al 2000) and IL-10 (Leghmari et al 2008). iNOS is also 
regulated by NF-κB (Xie et al 1994) and taken together; this seems to suggest that the 
possible action of BipB is through the NF-κB pathway inhibition.  
 Other groups have found that BipB can inhibit apoptosis and MNGC formation 
(Suparak et al 2005). However, this is most probably a T3SS3 defect as BipB is required 
for the proper delivery of T3SS3 effectors into the host cytosol. The authors did not show 
whether their BipB mutant could escape from the endosomes as it is known that the 
T3SS3 is required for escape from the endosomes (Muangsombut et al 2008), and that 
upon escape, it is the T6SS1 that is responsible for initiating MNGC formation (Chen et 
al 2011). 
It was found that BipB was highly conserved amongst 16 B. pseudomallei isolates 
as well as 3 B. mallei isolates, with at least 98% identity, showing the importance of this 
protein in pathogenic Burkholderia species (Druar et al 2007). 
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BipB is also homologous with the translocons of the T3SS of other bacteria. BipB 
shares 20-50% amino acid identity with SipB from Salmonella, YopB from Yersinia and 
IpaB from Shigella, all of which are important Gram-negative pathogens in humans. 
 These other homologues in other bacteria have been found to possess other 
functions. SipB from Salmonella and IpaB from Shigella have been found to directly bind 
caspase-1, and induce caspase-1-dependent cell death or pyroptosis (Hersh et al 1999, 
Chen et al 1996). YopB, the homologue of BipB in Yersinia pseudotuberculosis was 
found to have the exact opposite effect of what we observed with BipB. It was found that 
YopB can activate NF-κB, ERK, JNK and Ras, and lead to an increase in IL-8 secretion 
(Viboud et al 2003) which in turn was countered by other T3SS components in Yersinia 
pseudotuberculosis. This was the opposite of what we observed with B. pseudomallei , as 
BipB inhibits IL-8 secretion and a functional T3SS is required to induce IL-8 production. 
This may be due to some other components of the T3SS3 system being required to 
activate IL-8 production, whereas BipB suppresses IL-8 production. Bordetella, another 
bacterial pathogen secretes BopN, a T3SS effector into host cells where it blocks MAPK 
signalling and regulates NF-κB signalling to increase production of IL-10 to allow it to 
shut off the host inflammatory reaction (Nagamatsu et al 2009). In our case with BipB, 
its function is most probably to downregulate the expression of pro-inflammatory 
cytokines such as TNF-α, IL-6 and IL-8, through binding with host transcription factors. 
The down-regulation of IL-10, an immune-suppressive cytokine is probably a collateral 
effect observed when the other pro-inflammatory cytokines are inhibited by BipB. That 
may explain why both pro- and anti-inflammatory cytokines are inhibited by BipB as 
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these cytokines share many common promoter sites for various transcription factors to 
bind to it. 
 In conclusion, the action of BipB seems to be different from its homologues in 
Salmonella and Shigella. This translocator protein of the B. pseudomallei T3SS3 is an 
inhibitor of cytokine responses as well as a potent inhibitor of iNOS, and may be a key 
virulence factor utilised by B. pseudomallei to interfere with host immune responses so as 
to allow B. pseudomallei to survive inside mammalian hosts. BipB may be the factor 

















5.1 Role of IL-10 in melioidosis 
In conclusion, we have demonstrated an early and increased production of IL-10 
in our in vitro splenocyte model when comparing BALB/c-derived splenocytes with 
C57BL/6-derived splenocytes. IL-10 neutralization was shown to exhibit a protective 
effect in bone marrow-derived macrophages isolated from the susceptible BALB/c mice, 
in terms of reduction in bacterial loads when IL-10 is depleted. However, in vivo mouse 
infection failed to demonstrate any protective effect of IL-10 neutralization in the 
susceptible BALB/c mice. This could be due to the fact that IL-10 acts as a double edged 
sword, as excessive production of it leads to suppression of the immune system, yet 
inhibition of IL-10 leads to uncontrolled inflammation and immune pathology. Hence, 
IL-10 neutralization as a therapy may only be possibly useful in the early stages of 
infection in the susceptible BALB/c mice. Future experiments would include 
administration of different doses of anti-IL-10 antibodies for different durations (1, 2 or 3 
days) into the susceptible BALB/c mice prior to infection to check if the observed non-
efficacy of IL-10 neutralization treatment in this study was due to an insufficient dose of 
anti-IL-10 antibody administered.  In humans, the effects of IL-10 may not be a direct 
effect as we failed to see any improvement by in vitro infection of PBMCs. However, IL-
10 was found to be a strong predictor of mortality in melioidosis patients (Simpson et al 
Since PBMCs do not have any neutrophils, the main action of IL-10 may be on the 
neutrophils. It has been shown that IL-10 affects the neutrophil respiratory burst (Dang et 
al 2006), as well as reduces neutrophil recruitment to sites of infection (Sun et al 2009). 
Future experiments should be carried out with whole blood in vitro to include the effects 
of neutrophils. Neutrophils could also be isolated and the effects of IL-10 treatment on its 
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fuction studied in terms of respiratory burst as well as intracellular bacterial loads upon 
infection with B. pseudomallei.  
Another aspect that should be explored, with respect to the role of IL-10 in 
melioidosis would be to see if IL-10 has any role to play in mousee models of chronic 
melioidosis in C57BL/6 mice (Conejero et al 2011).   This is because in a related disease, 
tuberculosis, which shares many features with chronic melioidosis infection, IL-10 is 
upregulated in active tuberculosis patients and results in T-cell anergy, allowing 
Mycobacterium tuberculosis to survive and persist inside hosts (Gong et al 1996).  
In another study, it was shown that when IL-10 and another inhibitory cytokine, 
TGF-β were depleted, mice infected with M. tuberculosis showed decreased bacterial 
loads as compared to control groups without IL-10 depletion (Rosas-Taracos et al 2011). 
This shows that both IL-10 and TGF-β have synergistic effects on suppression of 
inflammatory cytokines. In fact, it was found that TGF-β is upregulated in melioidosis 
patients and that depleting TGF-β reduced bacterial loads in C57BL/6 mice (Weehuizhen 
et al 2012). However, in that study, the authors did not observe any improved survival in 
the in vivo mouse infection, with the administration of the TGF-β neutralizing antibody. 
This could be due to the compensatory effect of IL-10 on TGF-β, of which both are anti-
inflammatory cytokines. Future work should look into neutralization of both IL-10 and 
TGF-β in vivo to see if that translates into increased killing of B. pseudomallei during the 





5.2  Role of glutathione in melioidosis 
 For this part of the work, we have established an animal model that mimics the 
glutathione deficiency in diabetics when infected with B. pseudomallei. However, we 
performed this work in an acute infection model and with the more susceptible strain of 
mice, i.e. BALB/c. Future work should investigate chronic B. pseudomallei infection 
ofC57BL/6 mice (Conejero et al 2011) and whether inducing glutathione deficiency after 
the mice are chronically infected will cause recurrence of acute B. pseudomallei infection. 
We could also infect the relatively more resistant C57BL/6 mice with varying doses of B. 
pseudomallei in vivo after glutathione depletion to see whether this will reduce the LD50 
of B. pseudomallei required for infection. This will also reveal whether glutathione 
deficiency affects different strains of mice in their susceptibility to B. pseudomallei 
infection, and not just one particular strain. 
So far, we have established the link between glutathione deficiency and IL-12 and 
IFN-γ. However, IL-18 is also known to regulate the production of IFN-γ (Ceballos-
Olvera et al 2011) in mice, and it would be useful to see if glutathione levels will affect 
IL-18 production. Another cytokine, IL-15 has also been implicated as a co-stimulus 
required for the induction of IFN-γ, since depleting IL-15 in whole blood infection 
resulted in a slight decrease in IFN-γ production (Lauw et al 1999). 
In the related human study, we have investigated an ex vivo model of PBMC 
infection from normal human subjects, well-controlled diabetics, and poorly-controlled 
diabetics and found that glutathione deficiency contributes to poor control of B. 
pseudomallei infection. Since other underlying risk factors such as alcoholism, 
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thalassemia as well as renal failure, also causes chronic deficiency in glutathione, it 
would be useful to examine the PBMCs of patients with these risk factors, to find out if 
they exhibit the same phenotype upon B. pseudomallei infection. Knowledge from these 
other patients will serve to inform us that glutathione deficiency is an overarching theme 
underlying these risk factors to B. pseudomallei infection, and would allow us to design 
drugs or prophylaxis for susceptible members of the population, to reduce the risk of 
being infected with, as well as the severity of B. pseudomallei infection. 
Supplementation with NAC failed to demonstrate any improvement in terms of 
mortality in our in vivo mouse infection. This could be due to the mouse being at a 
healthy state without much oxidative stress, and further amelioration of the glutathione 
redox status by NAC supplementation would not have any additional positive benefit. 
Future work would include depletion of glutathione with DEM/BSO to cause a systemic 
glutathione deficiency, and then to supplement mice with NAC to see if NAC treatment 
could improve disease outcome in glutathione-depleted mice. Alternatively, this could 
also be due to the timing and dose of NAC supplementation which could be insufficient 
to boost the GSH levels. To investigate if this was the case, different doses of NAC could 
be fed to the mice before infection with B. pseudomallei.  
5.3 BipB as a novel modulator of cytokine secretion 
 In this project, we have identified BipB as a novel modulator in interfering with 
the production of pro-inflammatory cytokines as well as iNOS. Potential future work in 
this area would be to delineate the mechanisms involved in its suppression of the host 
immune defenses. One way to do so would be to transfect BipB with an epitope tag into 
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RAW 264.7 macrophages, and perform immuno-precipitation and 2-dimensional SDS 
PAGE gel to identify what proteins interact with BipB. To do so would require an 
improvement in transfection techniques as the current transfection efficiency into RAW 
264.7 macrophages is low (~10-20%), and it is also technically challenging to transfect 
U937 cells which is a suspension cell line. A more tedious approach would be to transfect 
in BipB and various transcription factors into HEK293T cells to see if there is any 
binding between BipB and the transcription factors through co-immuno-precipitation.  
Alternatively, we could utilize the yeast two-hybrid system to screen for binding 
partners to BipB, using a library of transcription effectors. However, this approach would 
assume that BipB directly binds to its target protein which may not always be the case as 
it may form a complex to bind to its target protein(s). Once the target protein(s) is/are 
identified, we could truncate away sections of BipB through molecular cloning to identify 
key regions responsible for its suppressive activity. We could then use site-directed 
mutagenesis on these key regions to identify the key residues responsible for its 
inhibitory activity.  
 We have found that the entry of B. pseudomallei was necessary for BipB to elicit 
its suppressive effects; it is likely that BipB is secreted inside host cells through T3SS. To 
better understand the process, we could generate monoclonal antibodies to native BipB, 
and visualize the localization of BipB protein over time using immuno-fluorescence 
microscopy, during the course of invasion in host cells.  
Since TssM is another effector protein secreted by B. pseudomallei, it would be 
necessary to examine the relationship between TssM and BipB in terms of their 
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eukaryotic targets that they bind to. Also, we would need to examine when TssM or BipB 
is expressed during infection of host cells to understand the temporal and spatial 
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